



医渡科技
YIDUTECH

Yidu Tech Inc.
醫渡科技有限公司

(incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock code 股份代號: 2158

2023/24
INTERIM REPORT
中期報告





Contents

Corporate Information	2
Key Financial and Operating Data	4
Financial Highlights	6
Business Overview	7
Management Discussion and Analysis	16
Corporate Governance and Other Information	23
Report on Review of Interim Financial Information	36
Interim Condensed Consolidated Statement of Comprehensive Income	38
Interim Condensed Consolidated Balance Sheet	40
Interim Condensed Consolidated Statement of Changes In Equity	42
Interim Condensed Consolidated Statement of Cash Flows	43
Notes to the Interim Condensed Consolidated Financial Information	44
Definitions	77

CORPORATE INFORMATION

Executive Directors

Ms. Gong Yingying (宮盈盈) (*Chairlady*)
Mr. Xu Jiming (徐濟銘) (*Chief Executive Officer*)
Dr. Yan Jun (閔峻)
Ms. Feng Xiaoying (封曉瑛)

Non-executive Director

Mr. Zeng Ming (曾鳴)

Independent non-executive Directors

Dr. Ma Wei-Ying (馬維英)
Ms. Pan Rongrong (潘蓉蓉)
Prof. Zhang Linqi (張林琦)

Audit Committee

Ms. Pan Rongrong (*Chairperson*)
Dr. Ma Wei-Ying
Prof. Zhang Linqi

Remuneration Committee

Dr. Ma Wei-Ying (*Chairperson*)
Ms. Gong Yingying
Prof. Zhang Linqi

Nomination Committee

Ms. Gong Yingying (*Chairperson*)
Dr. Ma Wei-Ying
Prof. Zhang Linqi

Joint Company Secretaries

Ms. Feng Xiaoying
Ms. Li Ching Yi

Authorized Representatives

Ms. Feng Xiaoying
Ms. Li Ching Yi

Headquarters

8/F Health Work
No. 9 Building of Huayuan North Road
Haidian District, Beijing, China

Principal Place of Business in Hong Kong

14th Floor, Golden Centre
188 Des Voeux Road Central, Hong Kong

Registered Office

Suite#4-210, Governors Square
23 Lime Tree Bay Avenue
PO Box 32311
Grand Cayman KY1-1209, Cayman Islands

Auditor

PricewaterhouseCoopers
*Certified Public Accountants and
Registered Public Interest Entity Auditor*
22/F, Prince's Building
Central, Hong Kong

Legal Advisers

As to Hong Kong and U.S. laws

Herbert Smith Freehills
23rd Floor, Gloucester Tower
15 Queen's Road Central, Hong Kong

As to PRC law

Han Kun Law Offices
9/F, Office Tower C1, Oriental Plaza
1 East Chang An Ave.
Dongcheng District, Beijing 100738, PRC

As to Cayman Islands law

Maples and Calder (Hong Kong) LLP
26th Floor, Central Plaza
18 Harbour Road, Wan Chai, Hong Kong

Hong Kong Share Registrar

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East, Wanchai, Hong Kong

Principal Share Registrar and Transfer Office

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square
Grand Cayman KY1-1102, Cayman Islands

Principal Banks

Citibank, N.A., Hong Kong branch
Citi Tower, One Bay East
83 Hoi Bun Road
Kwun Tong, Kowloon, Hong Kong

China CITIC Bank, Beijing branch,
Beijing Fuhua Mansion sub-branch
1st Floor, Tower E, Fuhua Mansion
8 Chaoyangmen North Street
Doncheng District, Beijing, China

Shanghai Pudong Development Bank, Beijing branch,
Dong Changan Street sub-branch
1st Floor, Tower B, Minsheng Financial Center
28 Jianguomen Inner Street
Dongcheng District, Beijing, China

Stock Code

2158

Company Website

www.yidutechgroup.com

KEY FINANCIAL AND OPERATING DATA

Performance Highlights under the “Focus” Strategy

Business Focus

Real world study business is the **flagship** brand in the industry. We have conducted **296** clinical trials projects¹ and **221** real-world study projects² in total.

For Shenzhen Hui Min Bao, we underwrote more than 6 million policies, and the insurance participation rate is more than **35%**.

Our chronic disease management business has achieved **milestone progress**:

- Significant breakthroughs** in innovative business models for digital therapeutics. Successfully selected into the healthcare service packages in Hainan Province. It is China's **first** provincial-level diabetes digital therapeutics project.
- For the first time**, we have integrated our diabetes digital therapeutics product into the health management fee-for-service for the Tianjin Hui Min Bao.

Disease Focus

Concentrate on key disease areas including **solid tumor, hematology, ophthalmology, immunology, cardiovascular** and **endocrine**.



Our disease registry covers nearly **80** disease areas.



Our disease registry covers more than **20** cancers.

Client Focus

Our gross profit margin increased by **12.1** percentage points to 38.2% year-on-year, the gross margins of each segment achieved an increase.



Covered **94** Top Hospital Clients



Covered **38** Regulators and Policymakers



Number of active customers for Life Science Solutions segment reached **131**, revenue retention rate for top 10 clients reached **128.2%**.



Provided operational services for “Jiangsu Province Hui Min Bao” and “Beijing Hui Min Bao” for **three consecutive years**.



As of September 30, 2023, the Group's backlog reached RMB **872** million, representing a **58.0%** year-on-year growth.

Organization Focus

The loss for the period reduced to RMB**79.56** million, representing a **77.7%** year-on-year decrease, adjusted net loss³ reduced to RMB**54.10** million, representing a **75.9%** year-on-year decrease.



Our net cash used in operating activities⁴ decreased by **11.8%** on a year-on-year basis.




Cash reserves⁵ reached RMB**3.81 billion**.

Note 1: Including clinical trial projects and clinical trials initiated by Investigator. Note 2: Including retrospective and prospective research projects. Note 3: We define “adjusted net loss” as loss for the period and adding back (i) share-based compensation expenses; and (ii) net foreign exchange losses. Note 4: Excluding the impact of third-party premiums collection and insurance claims. Note 5: Including cash and cash equivalents, deposits and financial assets.

1H FY2024 Financial Highlights


Gross Margin



Gross Margin by Segment

	1H FY23	1H FY24
Big Data Platform and Solutions	41.3%	45.2%
Life Sciences Solutions	14.5%	27.8%
Health Management Platform and Solutions	25.1%	53.2%

Loss (RMB million)




Note 1: We define “adjusted net loss” as loss for the period and adding back (i) share-based compensation expenses; and (ii) net foreign exchange losses.

Key Financial and Operating Data (Continued)


Intelligent Medical Brain - YiduCore

Based on the real-world study network driven by healthcare intelligence, refining the business loop encompassing “medical, pharmaceutical, insurance and patients”.



Note 1: CNITSEC — The China Information Technology Security Evaluate Center is an authoritative security evaluation facility. Note 2: CAICT — China Academy of Information and Communications Technology.


Financial Analysis



Balance Sheet Metrics



Net Cash Outflow from Operating Activities³ (RMB mn)



Note 1: Adjusted expenses excludes the share-based compensation. Note 2: Including cash and cash equivalents, deposits and financial assets. Note 3: Excluding the impact of third-party premiums collection and insurance claims.

FINANCIAL HIGHLIGHTS

Six months ended 30 September

	2023	2022	Change (%)
	(RMB'000, except percentages)		
Revenue	356,480	474,366	(24.9%)
— Big Data Platform and Solutions	127,939	124,028	3.2%
— Life Sciences Solutions	170,163	146,531	16.1%
— Health Management Platform and Solutions	58,378	203,807	(71.4%)
Gross profit	136,205	123,675	10.1%
Operating loss	(78,293)	(356,251)	(78.0%)
Loss for the period	(79,555)	(356,347)	(77.7%)
Non-IFRS adjusted net loss ⁽¹⁾	(54,100)	(224,802)	(75.9%)

(1) We define “adjusted net loss” as loss for the period and adding back (i) share-based compensation expenses; and (ii) net foreign exchange losses.

The Board did not recommend the distribution of an interim dividend for the six months ended 30 September 2023.

BUSINESS OVERVIEW

Significant breakthroughs in artificial intelligence (“AI”) technology are driving transformations of far-reaching significance and unveiling a future brimming with endless possibilities. Guided by the national strategy of high-quality development driven by innovation, the “14th Five-Year Plan” and the “Healthy China 2030”, China has implemented a series of regulations and guidance to promote the proprietary innovation in cutting-edge fields of science and technology such as AI and life and health.

Guided by our long-term goal of safe precision healthcare for all (“**green healthcare**”), Yidu Tech, as a leader in China’s healthcare intelligence industry, consistently adheres to proprietary innovation. From the supply side, we persistently propel the transformation of the healthcare industry, progressing from digitalization towards intelligentization, with the aim of attaining cost reduction and efficiency enhancement within the healthcare industry. Our intelligent “medical brain” YiduCore consists of algorithms and insightful medical knowledge based on real-world studies network with high-quality research grade evidence that are continuously accumulated and constantly iterated as we expand our use-case scenarios. In the new wave of AI innovation, we have been persistently upgrading and iterating our core algorithm, namely our proprietary large language model in the medical vertical field, based on quantifiable knowledge graphs accumulated from multi-dimensional practices. Accordingly, our intelligent “medical brain” YiduCore will also be upgraded from version 1.0 to version 2.0, and will empower various application scenarios in the healthcare industry, further enhancing our core competitiveness. As of 30 September 2023, upon authorization, YiduCore has processed and analyzed more than 4 billion medical records of over 900 million patients, covering more than 1,700 hospitals.

With the rapid development of AI technology, security is always the foundation of the Company. We have obtained the “Secure Multi-party Computing Basic Capability Special Evaluation Certificate (多方安全計算基礎能力專項評測證書)” and “Federated Learning Basic Capability Special Evaluation Certificate (聯邦學習基礎能力專項評測證書)” issued by China Academy of Information and Communications Technology (“CAICT”).

Since the second half of fiscal year (“FY”) 2023, we have committed to and diligently adhered to our “focus” strategy, concentrating on core businesses and key clients to enhance profitability. Prioritizing profit over business expansion, we have further solidified our business model, aiming for sustained long-term high-quality development. For the six months ended 30 September 2023, our revenue decreased by 24.9% year-on-year, mainly due to a heightened focus on the core business. Despite this, our loss for the period significantly reduced to RMB79.6 million, down 77.7% year-on-year, and the adjusted net loss decreased to RMB54.1 million, representing a year-on-year decrease of 75.9%. In addition, in terms of disease areas, we focus on key disease research areas such as solid tumors, hematologic disease, ophthalmology, immunity, cardiovascular and endocrine diseases. By consistently developing high-quality products and solutions, we aim to enhance customer experience, retaining key clients with a high revenue retention rate while meeting diverse demands of our customers. We achieved a 128.2% revenue retention rate for our top 10 clients in the Life Sciences Solutions segment. In the first half of FY2024, the synergies between business segments further strengthened, contributing to continuous improvement in overall operational efficiency. For the six months ended 30 September 2023, our gross margin increased by 12.1 percentage points year-on-year. Total operating expenses as a percentage of revenue decreased by 12.8 percentage points year-on-year. Our net cash outflow from operating activities decreased by 11.8% year-on-year excluding the impact of third-party premiums collection and insurance claims. As of 30 September 2023, our cash and cash equivalents reserves remain robust. Our management consistently integrates long-term perspective into strategic planning and daily decision-making, aiming for sustained and prudent growth in the long run.

Business Overview (Continued)

In response to the high incidence of chronic diseases, we focus on treatment. Based on YiduCore, evidence-based medicine, and traceable real-world evidence (“**RWE**”), we continuously research and develop digital therapeutics related to health management, and explore new models for chronic disease management. In FY2023, diabetes digital therapeutics product based on diabetes digital therapeutics developed by us has been approved by the U.S. Food and Drug Administration (“**FDA**”) and Hainan Medical Products Administration of China. During the Reporting Period, our diabetes digital therapeutics product has achieved milestone progress. As of 30 September 2023, the number of active users who have completed at least one transaction on our health management platform reached 26 million.

The essence of healthcare intelligence, based on innovative technologies such as artificial intelligence and big data, is to accelerate the quality and efficiency of medical evidence generation to address efficiency issues in research and treatment, making medical care safer, better, and more accessible. Leveraging a medical intelligence-driven real-world studies network, we continuously refine the business loop encompassing “medical, pharmaceutical, insurance, and patients”. From assisting doctors in clinical diagnosis and treatment to expediting new drug development, from empowering precise decision-making in public health to personalized proactive health management of many at every level, this comprehensive approach aligns with our vision and our commitment of building a value-based medical system since our inception.

YiduCore

YiduCore, our intelligent “medical brain”, can be understood in terms of three layers: the first layer consists of our medical data governance capabilities, which enable us to assist in aggregating and governing raw and scattered data from in-hospital and out-of-hospital information technology systems into structured and standardised high-quality data that can be analysed and processed by algorithmic models in an efficient, accurate and cost-efficient manner upon authorization. The second layer is composed of our continuously reinforced and expanded medical knowledge, insights, and disease models generated from and applied in our iterative and upgraded AI algorithms, as they are applied to our data-analytics driven solutions for our customers in various use-case scenarios. The final layer is based on the AI algorithm and disease research capabilities that run through the three application scenarios of research, diagnosis and treatment and public health, continuously iterate and upgrade our solutions, and refine the business loop encompassing “medical, pharmaceutical, insurance and patients”.

During the Reporting Period, we continuously focus on the research and development and training of large language model in the medical vertical field based on more than 100 billion fine-trained tokens, with model training for 7 billion and 13 billion parameters completed, and the training for 70 billion parameters underway. We plan to launch model versions with different parameter scales to meet the application needs of different terminals and scenarios. In the medical field, the high professionalism and low tolerance for fault determine the needs for high-quality professional large language model in the medical vertical field. Based on YiduCore's extensive accumulation of medical knowledge, knowledge graphs and high-quality medical data processing capability, we have an advantage in the development of large language model in the medical vertical field. Combined with our self-developed large language model that are continuously optimized and upgraded, the intelligent "medical brain" YiduCore will also be iteratively upgraded from version 1.0 to version 2.0. In terms of technology, the large language model in the medical vertical field developed on the basis of quantifiable knowledge graphs accumulated from the multi-dimensional practices keeps iterating YiduCore's core algorithm to enhance its semantic understanding and reasoning capabilities. Currently, our three business segments cover multiple application scenarios in the healthcare industry on the supply side, regulators, payer and demand side. YiduCore 2.0 will deeply empower our existing products and business lines to further enhance customer experience and product competitiveness.

We have continuously invested resources to deepen our understanding of diseases. The medical knowledge graphs in YiduCore are based on evidence-based medical research. As of 30 September 2023, the YiduCore medical knowledge graphs have covered over 100,000 medical subjects, of which the number of diseases covered by the disease knowledge graphs have exceeded 10,000. The continuous output of medical insights and quantifiable knowledge graphs accumulated from the multi-dimensional practices can drive multi-scenario applications, and the iterative integration of scenarios and algorithms has further reinforced our YiduCore. As of 30 September 2023, YiduCore has built disease models in nearly 80 disease areas. In terms of medical natural language processing, as of 30 September 2023, upon authorization, YiduCore has processed and analyzed more than 4 billion healthcare records from over 900 million patients, covering over 1,700 hospitals. Through such accumulation, YiduCore is able to accurately identify over 25,000 medical semantic fields.

Based on the intelligent "medical brain", YiduCore, we constantly improve the efficiency of research-grade evidence generation and deepen our research capability in different disease areas. In addition to the research on key diseases such as solid tumors, hematology, ophthalmology, immunology, cardiovascular and endocrine, we further deepened our research on other diseases. As of 30 September 2023, we have collaborated with experts and authoritative institutions to publish 19 disease standard datasets, including esophageal cancer, tuberculosis, mental illness, building as a foundation for multi-center research in relevant disease areas. Our comprehensive public health solutions provide large-scale simulation and prediction for efficient and dynamic decision-making. As of 30 September 2023, our public health solutions have been validated in 25 provinces and cities.

For security protection, we have obtained the "Secure Multi-party Computing Basic Capability Special Evaluation Certificate (多方安全計算基礎能力專項評測證書)" and "Federated Learning Basic Capability Special Evaluation Certificate (聯邦學習基礎能力專項評測證書)" issued by the CAICT. We have participated in the preparation of the Research Report on the Application of Privacy Computing (2022) (《隱私計算應用研究報告(2022年)》) issued by the Institute of Cloud Computing and Big Data of the CAICT, which promoted the development and standardization of privacy computing and other relevant technical specifications. We will continue to improve the security protection capabilities of YiduCore and jointly promote the improvement of data security capabilities of the healthcare industry.

Business Overview (Continued)

Big Data Platform and Solutions (“BDPS”)

In the BDPS segment, we provide data intelligence platform and data analytics-driven solutions for hospitals, healthcare institutions, regulators and policymakers. During the Reporting Period, the revenue of this segment was RMB127.9 million, representing a year-on-year increase of 3.2%. As of 30 September 2023, the number of top hospital clients increased by 6 from 31 March 2023 to 94, while the number of regulator and policymaker clients increased by 4 to 38.

For hospitals, we offer AI-enabled applications and solutions focused on three use-case scenarios, namely research, clinical diagnosis and treatment, and hospital operations management. The data analytics-driven applications and solutions we provide could further unlock the value of healthcare data to help clients conduct in-depth medical research and make precise and efficient decisions. By using our disease registries and disease research networks, top hospitals and experts can accelerate the production of research-grade evidence and scale up their clinical research in a faster and safer manner.

During the Reporting Period, we continue to promote the commercialization of our new hospital scenario intelligent solutions. Our All Disease Data Platform can deeply empower medical research by providing a full range of research tools including inspiration discovery, multi-modal medical record search, intelligent extraction, follow-ups, statistical analysis and AI modeling, which has been deployed and applied in several top research hospitals and Grade III-A hospitals, and was extensively used by more than 250 clinical research teams. YiduEywa2.0, our new-generation data centre, fully supports the requirements of information technology application innovation, providing comprehensive data lifecycle management and supporting multi-scenario data applications, assisting hospitals to use data assets more efficiently. During the Reporting Period, we consecutively constructed All Disease Data Platform and YiduEywa2.0 for a Grade III-A hospital in East China. We assisted the hospital to build the All Disease Data Platform, customizing the disease registry based on its key specialties, to meet the scientific research needs across the hospital. Additionally, we also assisted the hospital to build YiduEywa2.0 to enhance its capability in data asset management and refined hospital operation level.

We keep iterating real-world disease models by AI technologies, and continue to deepen our disease insights and engage top-grade hospitals and experts in our research network. In terms of hematologic disease, we won the bid for a national multi-centre big data platform project on hematologic disease for a Grade III-A hospital in East China during the Reporting Period, with a contract value of nearly RMB9 million. We aim to build a multi-centre collaboration platform that can serve the national alliance of hematologic clinical research centres (including 13 provincial level sub-centres and 64 contracted hospitals), and form an advanced hematologic disease registration system and cohort research service network, to improve the clinical research level of hematologic diseases in the centre. In terms of ophthalmic disease, the “Big Data Platform of National Clinical Research Centre for Ophthalmology” undertaken by us was officially launched during the Reporting Period. The platform was jointly developed by the Eye Hospital of Wenzhou Medical University and Yidu Tech, which will accelerate the development of clinical evaluation of ophthalmic drugs and medical devices, promote the clinical transformation of new technologies and therapies in ophthalmology. It has already completed the functional launch of seven specialized medical research platforms. In addition to deepening our research on key disease areas, we have also continuously expanded the breadth of our research in different disease areas. During the Reporting Period, we secured a number of disease registries projects in Grade III-A/Grade III hospitals, further strengthening our research capabilities in pediatrics, respiratory medicine, nephrology, and other disease areas.

We process and analyze more abundant and diverse data for regulators and policymakers. Upon authorization, we provide AI-enabled data analytics-driven solutions to regulators and policymakers, covering national/provincial/city-level regional platform development, and public health etc. With our AI-enabled analytical tools and cutting-edge simulation models, we also assist in building cities' "health brain" in the field of regional population health management. During FY2023, we won the bid for the construction of regional healthcare profiling for local residents in Beijing Chaoyang District, assisting in integrating residential medical data between hospitals in Chaoyang District to form an electronic health record for residents in Chaoyang District. During the Reporting Period, we further won the bid for the construction of medical supervision platform in Beijing Chaoyang District. Based on the medical big data platform in Chaoyang District, we helped build the operation and supervision analysis system of medical institutions and strengthened the intelligent monitoring for the operation of medical institutions in Chaoyang District. The contract value was nearly RMB10 million. We also assisted in constructing an infectious disease information platform for monitoring, warning and emergency command for a province in South China. By integrating multi-dimensional and multi-point data, including extensive disease data accumulated in work, and combining multi-point early warning and multi-dimensional prediction technologies, we help this province to better respond to new infectious diseases, unexplained diseases, and public health emergencies, and improve its pandemic monitoring, warning, and emergency response capabilities.

Life Sciences Solutions ("LSS")

In the LSS segment, we currently provide analytics-driven clinical development, real-world studies, and digital commercialization solutions in respect of the full life-cycle of drugs or medical devices from clinical development to post-market commercialization to meet the diverse needs of our customers.

Leveraging AI-enabled disease insights and continuously upgraded digital technology solutions, we assist partners in pharmaceuticals, biotechnology, medical devices and other clinical development processes reduce product development time and costs, improve the quality of clinical trials, and achieve commercial success.

As a pioneer in promoting the innovative intelligence clinical trials in China, in view of the issues of low enrollment rate, poor compliance, slow progress of clinical trials and high cost of drug development in traditional clinical trials, LSS segment has independently developed an integrated intelligence service platform, which mainly includes the intelligent Good Clinical Practice ("**iGCP**") and the Decentralized Clinical Trial Platform ("**DCT**"), based on the core capabilities of YiduCore, the network of top tier hospitals and experts accumulated in the BDPS segment under the guiding ideology of patient-centered drug development.

During the Reporting Period, based on the integrated intelligence service platform, we completed the patient recruitment ahead of schedule for the TAB014 phase III clinical trial of Zhaoke Ophthalmology and the phase III clinical trial of wet age-related macular degeneration for a biopharmaceutical company, respectively, and continued to rapidly advance the progress of the two phase III clinical trials.

Business Overview (Continued)

With accumulated experience in focused disease areas, especially for solid tumors, hematology, ophthalmology, immunology, cardiology and endocrine, and the continuous iteration and upgrading of intelligence service platform based on the YiduCore, we continuously strengthen our core competitiveness in the life science industry, improve repurchase rate of customers, and shorten the journey from molecules to patients. With our previous experience in completing the phase IIa clinical study project of a type of new drug for a large biopharmaceutical company with high quality, and high recognition from the client, the LSS segment once again successfully won the bid and signed the contract for the phase IIb clinical study project of this type of new drug during the Reporting Period. In addition, relying on our previous experience in successfully supporting a large domestic listed pharmaceutical company in its andrology phase III clinical trial, the LSS segment won the bid and signed a contract for an andrology phase III clinical trial project with an innovative pharmaceutical company during the Reporting Period. During the Reporting Period, the BDPS segment and the Eye Hospital of Wenzhou Medical University launched the “National Clinical Medical Research Centre for Eye Diseases Big Data Platform”. With the synergies between the segments and in-depth research in ophthalmic disease area, the LSS segment also won the bid for Eye Hospital of Wenzhou Medical University’s myopia IIT research project related to pediatric dietary management.

In the LSS segment, we have accumulated extensive experience through generating high-quality RWE to empower life science clients to manage and optimize the entire produce life-cycle, from pre-launch strategy development, regulatory approval support, peri-launch evidence support, post-market label extension, to efficacy and safety evaluation. With the first-ranked technical score and high recognition from our client, we continuously won three technically demanding retrospective real-world study projects related to cancer and pain from a multinational pharmaceutical company (“MNC”), and both parties have also established an exclusive strategic cooperation intention in this research field. In recent years, with the launch of the “Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovation Development of Traditional Chinese Medicine”(《中共中央國務院關於促進中醫藥傳承創新發展的意見》), for the Development of Traditional Chinese Medicine Informatization under the “14th Five-Year Plan” (《「十四五」中醫藥信息化發展規劃》) and other policies and measures, the development of traditional Chinese medicine has shown new vitality. The report of the 20th National Congress of Communist Party of China proposed “Promoting the Inheritance and Innovative Development of Traditional Chinese Medicine”. The new generation technologies such as big data and AI will provide strong support for the high-quality development of traditional Chinese medicine. Compared with Western medicine, the theoretical basis of traditional Chinese medicine is more complex and the dialectical challenge is greater. During the Reporting Period, by leveraging the accumulated rich experience and strong technical capabilities, the LSS segment successfully won the bid to assist a listed pharmaceutical company in expanding the indications of traditional Chinese medicine products by using RWE.

Over the past years, the LSS segment has maintained strong growth momentum, especially in the analytics-driven clinical development solutions. With COVID-19 pandemic coming to an end, the business of LSS segment has gradually recovered. As of the six months ended 30 September 2023, the segment's revenue amounted to RMB170.2 million, representing a year-on-year increase of 16.1%, and the gross margin increased by 13.3 percentage points year-on-year with the further improvement in operational efficiency. Through collaboration with other segments, we constantly innovate channels and improve business conversion between segments. As of 30 September 2023, we have performed 296 clinical researches, including clinical trials sponsored by pharmaceutical companies and researchers. We have performed 221 prospective and retrospective real-world studies. Our Intelligent Site Management Organization services have covered 304 clinical trial facilities. We focus on high-quality customers and continuously enhance customer experience by focusing on full life-cycle solutions empowered by digital and intelligent technology innovation. As of 30 September 2023, we achieved a 128.2% revenue retention rate for our top 10 clients in terms of revenue. 15 of the top 20 MNC are our clients.

We also have a team of professionals with rich experience and cross-domain expertise. As of 30 September 2023, our employees of the LSS segment have an average of over 9 years of relevant experience with expertise spanning clinical research, data science, epidemiology, biostatistics, medical informatics, AI and others. Through the development of a high-caliber talent pool, we continue to improve the operating efficiency of our projects.

Health Management Platform and Solutions (“HMPS”)

In this segment, we provide one-stop closed loop health management solutions, including chronic disease management services, commercial health insurance and Hui Min Bao (惠民保), a city-level supplementary insurance to the existing national social medical insurance, to provide multi-level healthcare solutions for city population. During the Reporting Period, the revenue of our HMPS segment amounted to RMB58.4 million, representing a year-on-year decrease of 71.4%, primarily due to streamlining our business portfolios.

In order to achieve our mission “to make value-based precision healthcare accessible to everyone”, we provide innovative insurance technologies and solutions to insurers, brokers and relevant regulators and policymakers in this sector. Leveraging our medical knowledge and insights accumulated through YiduCore, we continuously improve medical actuarial models, intelligent risk control models, and disease prediction models, and strengthen the construction of five core capabilities including patient analysis and risk assessment, customised product development, hierarchical classification of large-scale population, health intervention and intelligent customer service, intelligent underwriting and quick claim settlement. Our solutions aim to empower our customers with technology to design and develop innovative insurance products, enabling faster and more accurate insurance underwriting and expediting claim processing. In the future, we expect to leverage our independently developed large language model in the medical field to deeply empower our product lines, and strive to improve the creativity of health management services.

During the Reporting Period, we continue to increase the market penetration of the Hui Min Bao business. As of 30 September 2023, we cumulatively won the bid in and served 4 provinces and 12 cities, including Beijing, Shenzhen, Tianjin, Jiangsu Province, Fujian Province, Anhui Province, Shaanxi Province, etc. We focus on core cities to expand the regional network, and over 90% of our users are in China's top 15 provincial-level administrative regions in terms of GDP in 2022. We have assisted three of the four municipalities directly under the central government in China to launch the Hui Min Bao products, including Tianjin, Beijing and Chongqing.

Business Overview (Continued)

We have served as the main operation platform for Jiangsu Province Hui Min Bao (江蘇省惠民保), Beijing Hui Min Bao (北京惠民保) and Tianjin Hui Min Bao (天津惠民保) for two consecutive years, providing whole-process operational services including technology-driven product design, user acquisition, promotion, intelligent customer services and intelligent claim management. In addition to operational services, we also provided innovative value-added health management services for the Tianjin Hui Min Bao (天津惠民保), including early screening of critical illnesses, chronic disease consultations, online drug purchases and door-to-door nursing. In October and November 2023, we have respectively started the third year of sales of Jiangsu Province Hui Min Bao (江蘇省惠民保) and Beijing Hui Min Bao (北京惠民保).

As the main operation platform for Shenzhen Hui Min Bao (深圳惠民保), we underwrote more than 6 million policies, and the insurance participation rate is more than 35%. Both the number of policies and participation rate rank among the top in the Hui Min Bao programs across the country. The structure of the insured population of Shenzhen Hui Min Bao (深圳惠民保) shows a younger trend, with an average age of 34 years old, and more than 50% of the insured are under the age of 35. The younger generation have a greater awareness of insurance coverage.

We also deliver AI one-stop analytics-driven solutions by leveraging technology capabilities and medical knowledge accumulated by YiduCore, and offer integrated and personalized digital therapeutics that integrate traditional treatment with out-of-hospital care and lifestyle interventions, and continuously explore new models of chronic disease management. In FY2023, diabetes digital therapeutics product based on our diabetes digital therapeutics have been approved by FDA, and the diabetes digital therapeutics product targeted at the domestic market developed by us has also been granted the Medical Device Registration Certificate of the People's Republic of China issued by Hainan Medical Products Administration. During the Reporting Period, our diabetes digital therapeutics product has achieved milestone progress. For the first time, we have integrated our diabetes digital therapeutics product into the health management fee-for-service for the Tianjin Hui Min Bao (天津惠民保). Our innovative solution for diabetes digital therapeutics has been successfully selected into the "2+3" (referring to hypertension, diabetes, tuberculosis, hepatitis, and severe mental disorders) healthcare service packages in Hainan Province, and we will kick off the preliminary pilot campaign this year to promote the innovative application of digital therapeutics and support the Hainan's digital transformation in the healthcare industry. With our cutting-edge innovation capabilities and prominent practical achievements in the field of digital therapeutics, we have also been successfully selected as the "Best Innovative and Practice-enabled Companies at the World Digital Therapeutics Conference 2023 (2023世界數字療法大會最佳創新及實踐企業)". Our innovation strength and practical capabilities have been continuously recognized in the field of digital therapeutics, and further verified the feasibility of commercialization of digital therapeutics.

As of 30 September 2023, the number of active users who have completed at least one transaction on our health management platform reached 26 million.

Business Outlook

To achieve our mission to “make value-based precision healthcare accessible to everyone” and further solidify our leadership in the healthcare intelligence industry, we will continue to (i) upgrade and iterate the core algorithms, develop and optimize the large language model in the medical field, and increase the investment in intelligent “medical brain” YiduCore, to provide strong empowerment for various application scenarios in the medical field, (ii) deepen and broaden our analysis, research and use-cases in each key disease area, (iii) optimize the customer experience and improve operational efficiency in customer value delivery, (iv) improve synergy among the business sectors to increase penetration and repurchase rate among high-quality customers, (v) explore more opportunities in international markets, and (vi) enrich our ecosystem through strategic partnerships, investments and acquisitions.

In respect of BDPS segment, we will continue to strengthen our “two-pronged” strategy. Horizontally, we will continue to (i) expand our network of hospitals and urban regions, (ii) enrich the use-case scenarios of existing customers, and continuously enlarge our customer bases by product innovation, and (iii) continuously enhance the functionality, reliability and usability of our products in combination with state-of-art technology development. Vertically, we will continue to deepen and optimize our research within each key disease area by enabling multi-site research to be carried out based on disease dimensions and hospital networks.

In respect of LSS segment, with the constant development of AI technology, and the concept of “patient-centered” research and development being more integrated throughout full life-cycle of the medicine research and development, we will continue to accelerate the generation of research-grade evidence based on YiduCore to constantly optimize our one-stop solutions from analytics-driven clinical development to post-launch commercialization. Our focus will remain on the following areas: (i) the upgrade and iteration of our integrated intelligence service platform, and the improvement of operational efficiency based on the service platform, (ii) generation and application of RWE, (iii) key disease areas we excel at in clinical development, and (iv) preservation and enlargement of our customer base.

In respect of HMPS segment, we will continue to utilize our disease insights, knowledge and expert network to provide effective health management solutions to benefit more people with “patient-centered, outcome-oriented” care. We will continue to (i) increase the number of active users on our platform from diversified channels, (ii) expand our health management product offerings to meet the multi-level mass medical needs, (iii) explore new models of chronic disease management, and (iv) enrich user experience to solidify brand loyalty.

We are well positioned to serve as a leading player in the rapidly evolving healthcare intelligence industry. In the future, we will continue to introduce innovative AI-driven applications and solutions to capture the massive market opportunities in China and beyond, to enable stakeholders in the ecosystem to derive more value from our continuously iterating intelligent “medical brain”.

MANAGEMENT DISCUSSION AND ANALYSIS

Revenues

Our revenues decreased by 24.9% from RMB474.4 million for the six months ended 30 September 2022 to RMB356.5 million for the six months ended 30 September 2023. The decrease was primarily attributable to the decrease in revenue from Health Management Platform and Solutions segment.

Big Data Platform and Solutions. Revenue from Big Data Platform and Solutions remained relatively stable with an increase of 3.2% from RMB124.0 million for the six months ended 30 September 2022 to RMB127.9 million for the six months ended 30 September 2023.

Life Sciences Solutions. Revenue from Life Sciences Solutions increased by 16.1% from RMB146.5 million for the six months ended 30 September 2022 to RMB170.2 million for the six months ended 30 September 2023, primarily because our business started to recover, especially in the on-site implementation and delivery for clients, after the end of the COVID-19 pandemic.

Health Management Platform and Solutions. Revenue from Health Management Platform and Solutions decreased by 71.4% from RMB203.8 million for the six months ended 30 September 2022 to RMB58.4 million for the six months ended 30 September 2023, primarily due to streamlining our business portfolios.

Cost of Sales and Services

Our cost of sales and services decreased by 37.2% from RMB350.7 million for the six months ended 30 September 2022 to RMB220.3 million for the six months ended 30 September 2023. Share-based compensation expenses included in cost of sales and services were RMB3.0 million and RMB3.8 million for the six months ended 30 September 2022 and 2023 respectively. The decrease was caused by cost saving in the Health Management Platform and Solutions segment in the first half of fiscal year 2024.

Big Data Platform and Solutions. Cost of sales and services from the Big Data Platform and Solutions segment remained relatively stable with a decrease of 3.7% from RMB72.8 million for the six months ended 30 September 2022 to RMB70.1 million for the six months ended 30 September 2023.

Life Sciences Solutions. Cost of sales and services from Life Sciences Solutions remained relatively stable with a decrease of 2.0% from RMB125.3 million for the six months ended 30 September 2022 to RMB122.8 million for the six months ended 30 September 2023.

Health Management Platform and Solutions. Cost of sales and services from the Health Management Platform and Solutions segment decreased by 82.1% from RMB152.6 million for the six months ended 30 September 2022 to RMB27.4 million for the six months ended 30 September 2023, primarily due to the decrease in cost of pharmaceutical products and services from RMB139.5 million to RMB18.2 million.

Gross Profit and Gross Margin

As a result of the foregoing, our overall gross profit for the six months ended 30 September 2022 and 2023 were RMB123.7 million and RMB136.2 million respectively, and our overall gross margin was 26.1% and 38.2% respectively.

Big Data Platform and Solutions. Our gross margin in Big Data Platform and Solutions remained relatively stable with an increase from 41.3% for the six months ended 30 September 2022 to 45.2% for the six months ended 30 September 2023.

Life Sciences Solutions. Our gross margin in Life Sciences Solutions increased from 14.5% for the six months ended 30 September 2022 to 27.8% for the six months ended 30 September 2023, primarily due to the business recover and relatively stable cost of sales and services for the six months ended 30 September 2023.

Health Management Platform and Solutions. Our gross margin in Health Management Platform and Solutions increased from 25.1% for the six months ended 30 September 2022 to 53.2% for the six months ended 30 September 2023, primarily due to streamlining our business portfolios.

Selling and Marketing Expenses

Our selling and marketing expenses decreased by 16.5% from RMB124.1 million for the six months ended 30 September 2022 to RMB103.7 million for the six months ended 30 September 2023, primarily attributable to decrease in (i) employee benefits and expenses of employees engaging in selling and marketing function from RMB80.8 million to RMB69.6 million, which included share-based compensation of RMB5.3 million and RMB6.0 million in the respective periods; and (ii) business development, promotion and advertising expenses for the Group's marketing activities and insurance services from RMB28.2million to RMB20.5 million.

Selling and marketing expenses as a percentage of revenue increased from 26.2% for the six months ended 30 September 2022 to 29.1% for the six months ended 30 September 2023.

Administrative Expenses

Our administrative expenses decreased by 45.7% from RMB109.4 million for the six months ended 30 September 2022 to RMB59.4 million for the six months ended 30 September 2023, primarily attributable to decrease in employee benefits and expenses of employees engaging in administrative function from RMB91.4 million to RMB40.3 million, which included share-based compensation of RMB25.8 million and RMB7.2 million in the respective periods.

Administrative expenses as a percentage of revenue decreased from 23.1% for the six months ended 30 September 2022 to 16.7% for the six months ended 30 September 2023.

Management Discussion and Analysis (Continued)

Research and Development Expenses

Our research and development expenses decreased by 43.0% from RMB181.9 million for the six months ended 30 September 2022 to RMB103.6 million for the six months ended 30 September 2023. The decrease in research and development expenses was primarily due to (i) decrease in employee benefit and expenses for employees engaging in research and development function from RMB141.4 million to RMB70.1million, including share-based compensation of RMB10.2 million and RMB4.1 million in the respective periods, respectively as a result of the Company's focus of research and development on its core business; and (ii) decrease in technical and consulting services from RMB23.7 million to RMB14.8 million.

Research and development expenses as a percentage of revenue decreased from 38.3% for the six months ended 30 September 2022 to 29.1% for the six months ended 30 September 2023.

Operating Loss

As a result of the foregoing, operating loss generated from the Group decreased by 78.0% from RMB356.3 million for the six months ended 30 September 2022 to RMB78.3 million for the six months ended 30 September 2023.

Taxation

Income tax expense of the Group decreased from RMB1,836 thousand for the six months ended 30 September 2022 to RMB170 thousand for the six months ended 30 September 2023.

Loss for the Period

As a result of the foregoing, our loss for the period decreased by 77.7% from RMB356.3 million for the six months ended 30 September 2022 to RMB79.6 million for the six months ended 30 September 2023.

Non-IFRS Measure – Adjusted Net Loss

To supplement our consolidated financial statements which are presented in accordance with International Financial Reporting Standards (“IFRS”), we also use adjusted net loss (defined below) as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe that the presentation of this non-IFRS measure facilitates comparisons of operating performance from period to period and company to company by eliminating potential impact of items that our management does not consider to be indicative of our operating performance such as certain non-cash items and certain impact of investment transactions. We believe that this measure provides useful data to investors in understanding and evaluating the Group's consolidated results of operations in the same manner as they help our management. However, the use of non-IFRS measure has limitations as an analytical tool, and you should not consider them in isolation from, or as a substitute for analysis of, our results of operations or financial conditions as reported under IFRS. In addition, the non-IFRS financial measure may be defined differently from similar terms used by other companies.

We define “adjusted net loss” as loss for the period and adding back (i) share-based compensation expenses; and (ii) net foreign exchange losses.

For the six months ended 30 September 2022 and 2023, our adjusted net loss was RMB224.8 million and RMB54.1 million respectively.

Management Discussion and Analysis (Continued)

The table below sets forth the reconciliation of our non-IFRS financial measure for the six months ended 30 September 2022 and 2023 to the closest indicator prepared in accordance with IFRS.

	Six months ended	
	30 September	
	2023	2022
	(RMB'000)	
Loss for the period	(79,555)	(356,347)
Add:		
Share-based compensation expenses ⁽¹⁾	21,074	44,307
Net foreign exchange losses ⁽²⁾	4,381	87,238
Non-IFRS adjusted net loss	(54,100)	(224,802)
Non-IFRS adjusted net loss margin (%)⁽³⁾	(15.2%)	(47.4%)

(1) Share-based compensation expenses relate to the share awards we offered to our employees, directors and consultants under the Share Incentive Plans, which are primarily non-cash in nature and commonly not included in similar non-IFRS measures adopted by other companies in our industry.

(2) Net foreign exchange losses are primarily non-cash in nature and commonly not included in similar non-IFRS measures adopted by other companies in our industry.

(3) Represents non-IFRS adjusted net loss divided by the total revenue for the period indicated.

Liquidity and Capital Resource

For the six months ended 30 September 2023, we had funded our cash requirements principally from capital contribution from shareholders and financing through issuance and sales of convertible redeemable preferred shares in private placement transactions and the proceedings from initial public offering. We had cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balance and deposits of RMB3,522.0 million and RMB3,191.3 million as at 31 March 2023 and 30 September 2023 respectively.

Significant Investments

On 28 October 2022, Marvelous Panda Inc., a wholly-owned subsidiary of the Company, entered into a subscription agreement for the fund YD Capital I L.P. (the “**Fund**”) with the general partner and became a limited partner of the Fund by making a cash contribution of US\$40.0 million to the Fund, representing 40% of the fund commitment. As at 30 September 2023, the cash equivalent to US\$5.6 million was paid. The purpose of the Fund is primarily to (i) make venture investments in the healthcare sector; (ii) manage, supervise and dispose of such investments; and (iii) engage in such other activities incidental or ancillary thereto as the general partner deems necessary, appropriate or advisable.

Management Discussion and Analysis (Continued)

Material Acquisitions and Disposals

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies for the six months ended 30 September 2023.

Pledge of Assets

As at 30 September 2023, the Group had no material pledge of assets.

Future Plans for Material Investments or Capital Asset

As at 30 September 2023, the Group did not have detailed future plans for material investments or capital assets.

Foreign Exchange Exposure

During the Reporting Period, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of our Company, the subsidiaries and the consolidated affiliated entities that operate in the PRC, and the subsidiary that operates in Brunei are U.S. dollar, Renminbi and Brunei dollar respectively. During the six months ended 30 September 2023, we had currency exchange gain of RMB133.6 million and net foreign exchange loss of RMB4.4 million, as compared with currency exchange gain of RMB371.3 million and net foreign exchange loss of RMB87.2 million during the six months ended 30 September 2022. We did not hedge against any fluctuation in foreign currency during the six months ended 30 September 2022 and 2023.

Contingent Liabilities

As at 30 September 2023, we did not have any material contingent liabilities (as at 30 September 2022: nil).

Capital Commitment

As at 30 September 2023, capital commitment of the Group was RMB2.4 million (as at 30 September 2022: RMB17.1 million), mainly renovation expenses.

Investment Commitment

As at 30 September 2023, investment commitment of the Group was RMB260.5 million (as at 30 September 2022: RMB13.4 million), mainly for the outstanding contribution from Marvelous Panda Inc., a wholly-owned subsidiary of the Company, to the Fund YD Capital I L.P.

Management Discussion and Analysis (Continued)

Employees and Remuneration

As at 30 September 2023, the Group had a total of 944 employees, 480 employees were based in Beijing, 118 employees were based in Shanghai and 346 employees were based in other offices in China and overseas. The following table sets forth the total number of employees by function as at 30 September 2023:

Function	Number of employees
Product Development and Technology	376
Medical Function	331
Sales and Marketing	141
General and Administrative	96
Total	944

The total remuneration cost incurred by the Group for the six months ended 30 September 2023 was RMB262.5 million, as compared to RMB410.4 million for the six months ended 30 September 2022. The Company has also adopted and amended a Post-IPO Share Award Scheme and adopted a Post-IPO Share Option Scheme which was terminated on 25 August 2023 but the provisions of the Post-IPO Share Option Scheme shall remain in full force to the extent necessary to give effect to the exercise of any options granted prior to the termination.

Subsequent Event

As at the Latest Practicable Date, the Group has no significant events occurred after the Reporting Period which require additional disclosures or adjustments.

Management Discussion and Analysis (Continued)

Use of proceeds from global offering

On 15 January 2021, the shares of the Company were listed on the Main Board of the Stock Exchange. The net proceeds from the global offering (following full exercise of the Over-allotment Option, as defined in the prospectus of the Company dated 31 December 2020 (the “**Prospectus**”) were approximately RMB3,825 million (the “**Net Proceeds**”), which are intended to be applied in the manner set out in the Prospectus. There was no change in the intended use of proceeds as previously disclosed.

Set out below is the status of use of proceeds from the global offering as at 30 September 2023.

Purpose	% of use of proceeds	Net proceeds (RMB million)	Unutilised	Amount used	Unutilised	Expected time of full utilisation
			amount as at 31 March 2023 (RMB million)	for the six months ended 30 September 2023 (RMB million)	amount as at 30 September 2023 (RMB million)	
Strengthen our core capabilities	35%	1,339	1,085	137	948	31 March 2025
Further our business expansion	35%	1,339	614	360	254	31 March 2025
Further enrich our ecosystem through strategic partnerships, investments and acquisitions	20%	765	748	36	712	31 March 2025 ⁽¹⁾
Working capital and general corporate purposes	10%	382	263	43	220	31 March 2025

(1) In view of the volatile macroeconomic environment in recent years and the impact of the COVID-19 pandemic, the Board currently expects to fully utilize the net proceeds by 31 March 2025.

The above Net Proceeds were translated with spot rates on the Listing Date, while the cash and cash equivalents, term deposits, restricted bank balance and deposits as of 30 September 2023 were translated with spot rates on its balance sheet date.

As at 30 September 2023, the Company had utilised RMB1,691 million of the Net Proceeds.

Interim dividend

The Board does not recommend the distribution of an interim dividend for the six months ended 30 September 2023.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability, and the shares of the Company were listed on the Main Board of the Stock Exchange on 15 January 2021.

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders and to enhance corporate value and accountability.

Compliance with the Corporate Governance Code

During the Reporting Period, the Company has complied with the applicable provisions of the Corporate Governance Code (the “**Corporate Governance Code**”) set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), save for the following deviation.

Code provision F.1.1 of the Corporate Governance Code provides that the issuer should have a policy on payment of dividends and should disclose it in the annual report. As the Company intends to retain its available funds and earnings to fund the development and growth of our business, the performance of which will continue to be impacted by the relevant industry’s and economic outlook in the foreseeable future, the Board is of the opinion that it is not appropriate to adopt a dividend policy at this stage. The Board will review the Company’s status periodically and consider to adopt a dividend policy if and when appropriate.

The Company is committed to enhancing its corporate governance practices appropriate to the conduct and the growth of its business and to reviewing such practices from time to time to ensure that they comply with statutory and professional standards and align with the latest development. The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code, and maintain a high standard of corporate governance practices of the Company.

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix 10 of the Listing Rules as its own code of conduct regarding directors’ securities transactions.

Specific enquiry has been made of all the Directors and the relevant employees and they have confirmed that they have complied with the Model Code during the Reporting Period.

Model Code for Securities Transactions

The Company has adopted the Model Code as set out in Appendix 10 of the Listing Rules as its own code of conduct regarding directors’ securities transactions.

The Company’s relevant employees, who because of his/her office or employment, are likely to be in possession of inside information of the Company, are also subject to the Model Code.

Having made specific enquiries of all the Directors and the relevant employees, they have confirmed that they have complied with the Model Code during the Reporting Period.

Corporate Governance and Other Information (Continued)

Change in Directors' and the Senior Management's Information

Save as disclosed in this interim report, during the Reporting Period, there has been no change to the information of the Directors and the senior management which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company or Any of Its Associated Corporations

As at 30 September 2023, the interests and short positions of the Directors and chief executives of the Company in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which had been notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were recorded in the register required to be kept pursuant to section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

Name of Director	Nature of interest	Relevant entity	Number of Shares	Approximate % of interest ⁽¹⁾
Ms. Gong	Interest in controlled corporation/Interest of spouse	Sweet Panda Limited ⁽²⁾	417,626,975(L) ⁽³⁾	39.67%
Xu Jiming	Beneficial owner/Interest of spouse	Company	417,626,975(L) ⁽⁴⁾	39.67%
Yan Jun	Beneficial owner/Interest of spouse	Company	3,938,600(L) ⁽⁵⁾	0.37%
Feng Xiaoying	Beneficial owner	Company	2,810,700(L) ⁽⁶⁾	0.27%
Zeng Ming	Interest in controlled corporation	Perfect Sword Limited ⁽⁷⁾	2,163,845(L) ⁽⁸⁾	0.21%

Notes:

(1) The calculation is based on the total number of 1,052,858,149 Shares in issue as at 30 September 2023.

(2) Sweet Panda Limited is wholly-owned by Ms. Gong.

(3) Ms. Gong's spouse, Mr. Xu Jiming, holds 16,355,529 Shares and is entitled to receive up to 1,021,180 Shares pursuant to the exercise of options granted to him under the Pre-IPO Share Option Plans, subject to the conditions (including vesting conditions) of those options, 309,750 shares pursuant to the exercise of options granted to him under the Post-IPO Share Option Scheme, and 1,051,626 award shares granted to him under the Post-IPO Award Scheme. Ms. Gong is deemed to be interested in these Shares.

Corporate Governance and Other Information (Continued)

- (4) Represents Mr. Xu Jiming's holding of 16,355,529 Shares, entitlement to receive up to 1,021,180 Shares pursuant to the exercise of options granted to him under the Pre-IPO Share Option Plans, subject to the conditions (including vesting conditions) of those options, 309,750 Shares pursuant to the exercise of options granted to him under the Post-IPO Share Option Scheme, and 1,051,626 award shares granted to him under the Post-IPO Share Award Scheme. Sweet Panda Limited is wholly-owned by Ms. Gong, spouse of Mr. Xu Jiming, owns 398,888,890 Shares. Mr. Xu Jiming is deemed to be interested in these Shares.
- (5) Represents Mr. Yan Jun's entitlement to receive up to 2,500,640 Shares pursuant to the exercise of options granted to him under the Pre-IPO Share Option Plans, subject to the conditions (including vesting conditions) of those options, 1,090,500 Shares pursuant to the exercise of options granted to him under the Post-IPO Share Option Scheme, and 219,560 award shares granted to him under the Post-IPO Share Award Scheme, Ms. Liu Ning, spouse of Mr. Yan Jun, purchased 127,900 Shares in total. Mr. Yan Jun is deemed to be interested in the Shares held by Ms. Liu Ning.
- (6) Represents Ms. Feng Xiaoying's holding of 210,625 Shares, entitlement to receive up to 1,724,400 Shares pursuant to the exercise of options granted to her under the Post-IPO Share Option Scheme, and 875,675 award shares granted to her under the Post-IPO Share Award Scheme.
- (7) Perfect Sword Limited is controlled by Mr. Zeng Ming and his spouse, Ms. Tan Qing.
- (8) Represents Mr. Zeng Ming, through Perfect Sword Limited, is entitled to receive up to 750,000 Shares pursuant to the exercise of options granted to it under the Pre-IPO Share Option Plans, subject to the conditions (including vesting conditions) of these options, and 1,413,845 Shares exercised under the Pre-IPO Share Option Plans. Mr. Zeng Ming is deemed to be interested in these Shares.
- (9) The letter (L) denotes a long position in the Shares.

Save as disclosed above, as at 30 September 2023, none of the Directors and chief executives of the Company has any interest or short position in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to Model Code.

Corporate Governance and Other Information (Continued)

Substantial Shareholders' Interests and Short Positions in Shares and Underlying Shares

As at 30 September 2023, so far as our Directors are aware, the following persons (other than the Directors and chief executives whose interests have been disclosed in this interim report) had an interest or short position in the Shares or underlying Shares which would fall to be disclosed to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company, pursuant to Section 336 of the SFO:

Name of Shareholder	Capacity/Nature of interest	Number of Shares	Approximate% of interest ⁽¹⁾
Sweet Panda Limited ⁽²⁾	Beneficial interest	398,888,890	37.89%
Ms. Gong Yingying ⁽²⁾	Interest in a controlled corporation/ Interest of spouse	417,626,975	39.67%
Mr. Xu Jiming ⁽²⁾	Beneficial interest/Interest of spouse	417,626,975	39.67%
Sunshine Longevity Limited ⁽³⁾	Beneficial interest	96,068,715	9.12%
Sunshine Life Insurance Corporation Limited ⁽³⁾	Interest in a controlled corporation	96,068,715	9.12%
Sunshine Insurance Group Inc., Ltd. ⁽³⁾	Interest in a controlled corporation	96,068,715	9.12%

Notes:

- (1) The calculation is based on the total number of 1,052,858,149 Shares in issue as at 30 September 2023.
- (2) Sweet Panda Limited is wholly-owned by Ms. Gong. Ms. Gong's spouse, Mr. Xu Jiming, holds 16,355,529 Shares and is entitled to receive up to 1,021,180 Shares pursuant to the exercise of options granted to him under the Pre-IPO Share Option Plans, subject to the conditions (including vesting conditions) of those options, 309,750 Shares pursuant to the exercise of options granted to him under the Post-IPO Share Option Scheme, and 1,051,626 award shares granted to him under the Post-IPO Award Scheme. Ms. Gong is deemed to be interested in these Shares.
- (3) Sunshine Longevity Limited is wholly-owned by Sunshine Life Insurance Corporation Limited, which is a non-wholly owned subsidiary of Sunshine Insurance Group Inc., Ltd. Under the SFO, each of Sunshine Life Insurance Corporation Limited and Sunshine Insurance Group Inc., Ltd. is deemed to be interested in the Shares held by Sunshine Longevity Limited.

Save as disclosed herein, as at 30 September 2023, no person, other than the Directors and chief executives whose interests are set out in this interim report, had any interests or short positions in the Shares or underlying Shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

Share Schemes

Pre-IPO Share Option Plans

The two Pre-IPO Share Option Plans of the Company were approved and adopted pursuant to a shareholders' resolution of the Company passed on 16 March 2015 (the "**Pre-IPO ESOP I**" and the "**Pre-IPO ESOP II**", respectively). No options will be granted under the Pre-IPO Share Option Plans after the Listing Date.

The purposes of the Pre-IPO Share Option Plans are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to selected employees, directors, and consultants of the Group and to promote the success of the Company's business by offering these individuals or entities an opportunity to acquire a proprietary interest in the success of the Company.

Persons eligible to participate in the Pre-IPO Share Option Plans include employees, including officers and directors, of the Group and consultants of the Group or any parent company of the Company.

As of 30 September 2023, the Company has granted options under the Pre-IPO Share Option Plans to 1,173 grantees. The exercise price of the options under the Pre-IPO Share Option Plans is between US\$0.0028 per Share and US\$2.56 per Share. No consideration was payable by the grantees for the grant of options under the Pre-IPO Share Option Plans. As of 30 September 2023, under the Pre-IPO Share Option Plans, 104,294,513 options have been exercised, 396,160 options have been cancelled and 9,877,090 options have lapsed. The aggregate number of Shares underlying the outstanding options as at 30 September 2023 were 35,867,407 Shares, represents approximately 3.41% of the issued Shares.

Each of the Pre-IPO Share Option Plans commenced on 16 March 2015 and shall continue in effect for a term of ten years. Further details of the Pre-IPO Share Option Plans are set out in the Prospectus.

Corporate Governance and Other Information (Continued)

Details and movements of the outstanding options granted under the Pre-IPO ESOP I during the Reporting Period are as follows:

Name of participant or category of participant	Role	Date of grant	Vesting period ⁽¹⁾	Exercise price (US\$)	Weighted average closing price immediately before the dates on which the options were exercised (HK\$)	Outstanding as of 1 April 2023	Share options granted during the Reporting Period ⁽²⁾	Exercised during the Reporting Period	Lapsed during the Reporting Period	Cancelled during the Reporting Period	Outstanding as of 30 September 2023
Directors of the Company											
Xu Jiming	Executive Director	24 August 2016	4 years	0.018	6.74	15,000,000	—	15,000,000	—	—	—
		1 December 2020	0 year	0.018	—	50,000	—	—	—	—	50,000
Employees											
In aggregate		9 December 2014 to 1 December 2020	2-4 years	0.0028-0.018	—	12,088,985	—	—	80,000	—	12,008,985
Total					6.74	27,138,985	—	15,000,000	80,000	—	12,058,985

Notes:

- (1) The exercise period of the options granted under Pre-IPO ESOP I shall commence from the date on which the relevant options become vested and end on the 10th anniversary of the grant date, subject to the terms of the Pre-IPO ESOP I and the share option award agreement signed by the grantee.
- (2) No option was granted under the Pre-IPO ESOP I during the Reporting Period, therefore there is no corresponding (1) closing price of the share immediately before the date on which the options were granted, (2) fair value of options at the date of grant and (3) accounting standard and policy adopted to be included.

Corporate Governance and Other Information (Continued)

Details and movements of the outstanding options granted under the Pre-IPO ESOP II during the Reporting Period are as follows:

Name of participant or category of participant	Role	Date of grant	Vesting period ⁽¹⁾	Exercise price (US\$)	Weighted average closing price immediately before the dates on which the options were exercised (HK\$)	Outstanding as of 1 April 2023	Share options granted during the Reporting Period ⁽²⁾	Exercised during the Reporting Period	Lapsed during the Reporting Period	Cancelled during the Reporting Period	Outstanding as of 30 September 2023
Directors of the Company											
Yan Jun	Executive Director	30 December 2019	4 years	0.018	7.32	208,375	—	104,185	—	—	104,190
		1 December 2020	4 years	0.018	—	583,255	—	—	—	—	583,255
		11 December 2020	1 year	0.018	—	640	—	—	—	—	640
Xu Jiming	Executive Director	30 December 2019	4 years	0.018	6.74	2,282,145	—	1,311,605	—	—	970,540
		11 December 2020	1 year	0.018	—	640	—	—	—	—	640
Employees											
In aggregate		3 July 2015 to 11 December 2020	2-4 years	0.018-0.0028	7.38	20,005,362	—	405,060	682,910	—	18,917,392
Service providers⁽³⁾											
In aggregate		1 October 2017 to 11 December 2020	0-5 years	0.018-2.56	—	3,231,765	—	—	—	—	3,231,765
Total					6.74-7.38	26,312,182	—	1,820,850	682,910	—	23,808,422

Notes:

- (1) The exercise period of the options granted under Pre-IPO ESOP II shall commence from the date on which the relevant options become vested and end on the 10th anniversary of the grant date, subject to the terms of the Pre-IPO ESOP II and the share option award agreement signed by the grantee.
- (2) No option was granted under the Pre-IPO ESOP II during the Reporting Period, therefore there is no corresponding (1) closing price of the share immediately before the date on which the options were granted, (2) fair value of options at the date of grant and (3) accounting standard and policy adopted to be included.
- (3) Service providers of the Company provides services including but not limited to project design, market analysis, management consulting and technical consulting. The grant of option to the service providers is to remunerate and compensate them for their continuing services to the Group in the same manner the Company remunerate and compensate other employees of the Group, which serves the purpose of the Post-IPO Share Option Scheme i.e. to provide selected participants with the opportunity to acquire proprietary interests in the Company and to encourage the selected participants to work towards enhancing the value of the Company and its Shares for the benefit of the Company as a whole.

Corporate Governance and Other Information (Continued)

Post-IPO Share Award Scheme

The Post-IPO Share Award Scheme was conditionally adopted pursuant to the resolutions of the Shareholders on 28 December 2020.

The purpose of the Post-IPO Share Award Scheme is to align the interests of eligible persons with those of our Group through ownership of Shares, dividends and other distributions paid on Shares and/or the increase in value of the Shares, and to encourage and retain eligible persons to make contributions to the long-term growth and profits of our Group.

Any individual, being an employee, director, officer, consultant, adviser, distributor, contractor, customer, supplier, agent, business partner, joint venture business partner or service provider of any member of our Group or any affiliate of the Group who the Board or its delegate(s) considers, in its sole discretion, to have contributed or will contribute to our Group is eligible to receive an award.

On 25 August 2023, the Board resolved to cancel and propose to re-grant 3,184,506 share awards to 9 awardees ("**Existing Grantees**") pursuant to the terms of the Post-IPO Share Award Scheme. The shareholders of the Company approved the adoption of the scheme mandate limit at the Company's 2023 annual general meeting, hence the condition to re-granting the 3,184,506 share awards to the Existing Grantees have been fulfilled as disclosed in the Company's announcement dated 25 August 2023.

It was also approved at the Company's 2023 annual general meeting that the Post-IPO Share Award Scheme is amended to bring it in line with the amendments to the Listing Rules. The awards granted under the Post-IPO Share Award Scheme prior to the amendment, but not yet vested shall continue to be valid and be vested in accordance with the amended Post-IPO Share Award Scheme.

The scheme mandate limit shall not exceed 10% of the total number of Shares in issue to all share schemes adopted by the Company from time to time. The said scheme mandate limit shall be 105,285,814 Shares, on the basis that there are a total of 1,052,858,149 Shares in issue on the date of approval of the amendment of the Post-IPO Share Award Scheme, being 28 September 2023. In addition, the total number of awards and/or share options which may be granted under the Post-IPO Share Award Scheme and any other share schemes of the Company to the service providers from time to time shall not exceed 1% of the total number of Shares in issue on the date of approval of the amendment of the Post-IPO Share Award Scheme, being 28 September 2023. Thus, the service provider sublimit in respect of the share schemes of the Company shall be 10,528,581 Shares.

During the Reporting Period, 10,340,160 Shares had been granted, 1,512,615 awards have been cancelled and 3,079,998 awards have lapsed under the Post-IPO Share Award Scheme. The total number of awards available for grant under the Post-IPO Share Award Scheme was 102,473,808 Shares, representing 9.73% of the issued shares capital of the Company as at the Latest Practicable Date.

Corporate Governance and Other Information (Continued)

The Post-IPO Share Award Scheme shall be valid and effective for ten years from the Listing Date (after which no awards will be granted), and thereafter for so long as there are any non-vested Shares granted prior to the expiration of the Post-IPO Share Award Scheme, for the purpose of giving effect to the vesting of such Shares or otherwise as may be required in accordance with the provisions of the Post-IPO Share Award Scheme. The vesting period of the Post-IPO Share Award Scheme ranges from 0 to 4 years. Besides that, the vesting of the awards is subject to the award grantee(s) meeting the performance targets to be determined by the Company from time to time. The Company has established an appraisal mechanism to assess the fulfilment of performance targets by its Directors, chief executive and employees, which are linked to the Company's strategic goals and values.

Further details of the Post-IPO Share Award Scheme are set out in the circular of the Company dated 25 August 2023.

Details and movement of the outstanding awards granted under the Post-IPO Share Award Scheme during the Reporting Period are as follows⁽¹⁾:

Name of participant or category of participant	Role	Date of grant	Vesting period	Closing price of shares immediately before the dates on which the awards were granted (HK\$)	Weighted average closing price immediately before the dates on which the awards were vested (HK\$)	Fair value at the date of grant (HK\$) ⁽²⁾	Outstanding as of 1 April 2023	Share awards		Lapsed during the Reporting Period	Cancelled during the Reporting Period	Outstanding as of 30 September 2023
				on which the awards were granted (HK\$)	on which the awards were vested (HK\$)			granted during the Reporting Period ⁽³⁾	Share awards vested during the Reporting Period			
Directors of the Company												
Xu Jiming	Executive Director	1 October 2021	4 years	25.85	6.06	—	77,438	—	25,812	—	—	51,626
		25 August 2023	4 years	4.13	—	4,140,000	—	1,000,000	—	—	—	1,000,000
Yan Jun	Executive Director	25 August 2023	4 years	4.13	—	908,978	—	219,560	—	—	—	219,560
Feng Xiaoying	Executive Director	1 July 2021	4 years	40.80	5.92	—	222,000	—	111,000	—	—	111,000
		1 October 2022	4 years	4.82	5.76	—	398,500	—	99,625	—	—	298,875
		25 August 2023	4 years	4.13	—	1,928,412	—	465,800	—	—	—	465,800
Employees												
In aggregate		1 July 2021	0-4 years	40.80	5.81	—	1,748,108	—	722,628	358,830	—	666,650
		1 October 2021	1-4 years	25.85	5.92	—	650,438	—	41,237	36,200	—	573,001
		1 January 2022	2-4 years	21.05	6.06	—	701,850	—	17,925	230,775	—	453,150
		1 April 2022	4 years	9.79	—	—	81,200	—	—	12,700	—	68,500
		1 July 2022	0-4 years	9.36	6.03	—	1,461,600	—	255,267	314,373	62,035	829,925
		1 October 2022	4 years	4.82	6.03	—	8,712,175	—	1,573,410	1,327,045	359,980	5,451,740
		16 January 2023	4 years	6.90	—	—	55,300	—	—	30,000	—	25,300
		1 April 2023	4 years	7.32	—	1,909,056	—	260,800	—	—	—	260,800
		25 August 2023	4 years	4.13	—	34,751,160	—	8,394,000	—	770,075	1,090,600	6,533,325
Service providers⁽⁴⁾												
In aggregate		1 July 2021	1-4years	40.80	8.13	—	21,675	—	20,400	—	—	1,275
		1 October 2021	1-2years	25.85	8.56	—	1,700	—	1,700	—	—	—
		1 January 2022	3-4years	21.05	8.20	—	114,400	—	40,200	—	—	74,200
Total				4.13-40.80	5.76-8.56	43,637,606	14,246,384	10,340,160	2,909,204	3,079,998	1,512,615	17,084,727

Corporate Governance and Other Information (Continued)

Notes:

- (1) No amount was paid by selected participants on application or acceptance of the award shares granted to them under the Post-IPO Share Award Scheme.
- (2) Details of the valuation of share award of the Company during the Reporting Period is set out in Note 26 to the consolidated financial statements.
- (3) The vest of the award is subject to the award grantee(s) meeting the performance targets to be determined by the Company from time to time. The Company has established an appraisal mechanism to assess the fulfilment of performance targets by its Directors, chief executive and employees, which are linked to the Company's strategic goals and values. The appraisal mechanism uses a scoring system based on a matrix of qualitative and quantitative indicators that vary according to the roles and responsibilities of the relevant Directors, chief executive and employees. The indicators include, but are not limited to, measures of work quality, efficiency, collaboration, management and strategy. The scoring system evaluates the Directors, chief executive and employees' regular duties and the strategic objectives or tasks assigned for the appraisal period. The Company intends to make reference to this appraisal mechanism to set and review the performance targets of the award grantees periodically.
- (4) Service providers of the Company provides services including but not limited to project design, market analysis, management consulting and technical consulting. The grant of award to the service providers is to remunerate and compensate them for their continuing services to the Group in the same manner the Company remunerate and compensate other employees of the Group, which serves the purpose of the Post-IPO Share Award Scheme i.e. to provide selected participants with the opportunity to acquire proprietary interests in the Company and to encourage the selected participants to work towards enhancing the value of the Company and its Shares for the benefit of the Company as a whole.

Corporate Governance and Other Information (Continued)

Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme was conditionally adopted pursuant to the resolutions of the Shareholders on 28 December 2020. Pursuant to the resolution of the Board on 25 August 2023, the Post-IPO Share Option Scheme was terminated.

During the Reporting Period, 6,058,500 options have been granted, 1,326,400 options have been cancelled and 1,842,250 options have lapsed under the Post-IPO Share Option Scheme. The Post-IPO Share Option Scheme shall remain in full force to the extent necessary to give effect to the exercise of any options granted prior to the termination. As at the Latest Practicable Date, there are 19,023,737 granted but unexercised options.

Further details of the Post-IPO Share Option Scheme are set out in the Prospectus.

Details and movement of the outstanding options granted under the Post-IPO Share Option Scheme during the Reporting Period are as follows:

Name of participant or category of participant	Role	Date of grant	Vesting period ⁽¹⁾	Exercise price (HK\$)	Closing price of shares immediately before the dates on which the options were granted (HK\$)	Weighted average closing price of the dates on which the options were exercised (HK\$)	Fair value at the date of grant (HK\$) ⁽²⁾	Outstanding as of 1 April 2023	Share options granted		Lapsed during the Reporting Period	Cancelled during the Reporting Period	Outstanding as of 30 September 2023
					options granted (HK\$)	the options were exercised (HK\$)			during the Reporting Period ⁽³⁾	Exercised during the Reporting Period			
Directors of the Company													
Yan Jun	Executive Director	3 July 2023	4 years	5.91	5.75	—	2,747,998	—	1,090,500	—	—	—	1,090,500
Xu Jiming	Executive Director	29 July 2021	4 years	34.52	32.50	—	—	309,750	—	—	—	—	309,750
Feng Xiaoying	Executive Director	22 April 2022	0 year	8.83	8.44	—	—	612,900	—	—	—	—	612,900
		10 October 2022	4 years	4.80	4.51	—	—	512,400	—	—	—	—	512,400
		3 July 2023	4 years	5.91	5.75	—	1,551,689	—	599,100	—	—	—	599,100
Employees													
In aggregate		29 July 2021	4 years	34.52	35.25	—	—	2,003,137	—	—	148,700	—	1,854,437
		10 October 2022	3-4 years	4.80	4.51	6.00	—	12,938,925	—	117,425	1,693,550	1,304,700	9,623,250
		3 July 2023	4 years	5.91	5.75	—	10,806,620	—	4,368,900	—	—	21,700	4,347,200
Service providers⁽⁴⁾													
In aggregate		29 July 2021	4 years	34.52	32.50	—	—	10,900	—	—	—	—	10,900
Total					4.51-35.25	6.00	15,106,287	16,388,012	6,058,500	117,425	1,842,250	1,326,400	19,160,437

Corporate Governance and Other Information (Continued)

Notes:

- (1) The exercise period of the options granted under Post-IPO Share Option Scheme shall commence from the date on which the relevant options become vested and end on the 10th anniversary of the grant date, subject to the terms of the Post-IPO Share Option Scheme and the share option award agreement signed by the grantee.
- (2) Details of the valuation of share option of the Company during the Reporting Period is set out in Note 26 to the consolidated financial statements.
- (3) The exercise of the option is subject to the option grantee(s) meeting the performance targets to be determined by the Company from time to time. The Company has established an appraisal mechanism to assess the fulfilment of performance targets by its Directors, chief executive and employees, which are linked to the Company's strategic goals and values. The appraisal mechanism uses a scoring system based on a matrix of qualitative and quantitative indicators that vary according to the roles and responsibilities of the relevant Directors, chief executive and employees. The indicators include, but are not limited to, measures of work quality, efficiency, collaboration, management and strategy. The scoring system evaluates the Directors, chief executive and employees' regular duties and the strategic objectives or tasks assigned for the appraisal period. The Company intends to make reference to this appraisal mechanism to set and review the performance targets of the option grantees periodically.
- (4) Service providers of the Company provides services including but not limited to project design, market analysis, management consulting and technical consulting. The grant of option to the service providers is to remunerate and compensate them for their continuing services to the Group in the same manner the Company remunerate and compensate other employees of the Group, which serves the purpose of the Post-IPO Share Option Scheme i.e. to provide selected participants with the opportunity to acquire proprietary interests in the Company and to encourage the selected participants to work towards enhancing the value of the Company and its Shares for the benefit of the Company as a whole.

The number of shares that may be issued in respect of options and awards granted under all schemes of our Company during the Reporting Period divided by the weighted average number of shares of the relevant class in issue for the year is 1.56%.

The number of options and awards available for grant under the scheme mandate at the beginning and the end of the Reporting Period is as follows:

	As of 1 April 2023	As of 30 September 2023
Options available for grant under the Post-IPO Share Option Scheme	73,507,114	—
Awards available for grant under the Post-IPO Share Award Scheme	27,021,094	102,473,808
— Awards available for grant under the service provider sublimit as part of the scheme mandate	— ⁽¹⁾	10,528,581
Total options and awards available for grant under the scheme mandate	100,528,208	102,473,808

Note:

- (1) The service provider sublimit was adopted on 28 September 2023.

Directors' Rights to Acquire Shares or Debentures

Save as otherwise disclosed in this interim report, at no time during the Reporting Period, was the Company or any of its subsidiaries a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of Shares in, or debentures of, the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

Purchase, Sale or Redemption of Listed Securities

During the Reporting Period, neither the Company nor any of its subsidiaries or consolidated attributed entities has purchased, sold or redeemed any of the Company's listed securities.

Audit Committee

The Group has established an audit committee comprising three members, being Dr. Ma Wei-Ying, Ms. Pan Rongrong and Prof. Zhang Linqi, with Ms. Pan Rongrong (being the Company's independent non-executive Director with the appropriate professional qualifications) as chair of the audit committee.

The audit committee has reviewed the consolidated financial information of the Group for the six months ended 30 September 2023 and has met with the independent auditor, PricewaterhouseCoopers. The audit committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control and financial reporting matters with senior management members of the Company.

Auditors Scope of Work

The Company's external auditor, PricewaterhouseCoopers, has performed a review of the Group's unaudited interim condensed consolidated financial information for the six months ended 30 September 2023 in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". PricewaterhouseCoopers confirmed that nothing has come to their attention that causes them to believe that the interim financial information is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

On behalf of the Board

Ms. Gong Yingying

Chairlady and Founder

Hong Kong, 29 November 2023

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION



羅兵咸永道

To the Board of Directors of Yidu Tech Inc.

(incorporated in the Cayman Islands with limited liability)

Introduction

We have reviewed the interim financial information set out on pages 38 to 76, which comprises the interim condensed consolidated balance sheet of Yidu Tech Inc. (the “Company”) and its subsidiaries (together, the “Group”) as at 30 September 2023 and the interim condensed consolidated statement of comprehensive income, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six months then ended, and notes, comprising material accounting policy information and other explanatory information. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 “Interim Financial Reporting”. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 “Interim Financial Reporting”. Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PricewaterhouseCoopers, 22/F Prince’s Building, Central, Hong Kong
羅兵咸永道會計師事務所 · 香港中環太子大廈22樓
T: +852 2289 8888, F: +852 2810 9888, www.pwchk.com

Report on Review of Interim Financial Information (Continued)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 “Interim Financial Reporting”.

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong, 29 November 2023

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Note	Six months ended 30 September	
		2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Revenue from contracts with customers	6	356,480	474,366
Cost of sales and services	6, 9	(220,275)	(350,691)
Gross profit		136,205	123,675
Selling and marketing expenses	9	(103,663)	(124,106)
Administrative expenses	9	(59,425)	(109,366)
Research and development expenses	9	(103,583)	(181,850)
Net impairment losses on financial assets and contract assets	6,18,19	(20,297)	(11,501)
Other income	7	72,333	37,528
Other gains/(losses) — net	8	137	(90,631)
Operating loss		(78,293)	(356,251)
Finance income		4,639	3,932
Finance costs		(946)	(1,639)
Finance income — net	10	3,693	2,293
Share of losses from investments in associates	11	(4,785)	(553)
Loss before income tax		(79,385)	(354,511)
Income tax expense	12	(170)	(1,836)
Loss for the period		(79,555)	(356,347)
Loss is attributable to:			
Owners of the Company		(75,769)	(353,517)
Non-controlling interests		(3,786)	(2,830)
		(79,555)	(356,347)

Interim Condensed Consolidated Statement of Comprehensive Income (Continued)

	Note	Six months ended 30 September	
		2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Other comprehensive income			
<i>Item that will not be reclassified to profit or loss:</i>			
Currency translation differences		297,759	681,126
<i>Item that will be reclassified to profit or loss :</i>			
Currency translation differences		(164,128)	(309,840)
Other comprehensive income for the period, net of tax		133,631	371,286
Total comprehensive income for the period		54,076	14,939
Total comprehensive income for the period is attributable to:			
Owners of the Company		52,803	15,154
Non-controlling interests		1,273	(215)
		54,076	14,939
Loss per share, basic and diluted (RMB)	13	(0.07)	(0.36)

The above interim condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

	Note	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Assets			
Non-current assets			
Property, plant and equipment	14	92,645	72,584
Right-of-use assets	15	13,760	11,249
Intangible assets	16	39,704	39,531
Deferred income tax assets	29	173	345
Investments accounted for using the equity method	11	36,864	5,282
Financial assets at fair value through profit or loss	21	20,819	23,115
Pledged bank deposits	22	5,104	1,262
Investments measured at amortized cost	17	—	240,510
Restricted bank balance and deposits	22	6,251	6,208
Total non-current assets		215,320	400,086
Current assets			
Inventories	20	3,733	3,733
Contract assets	6	104,724	123,706
Trade receivables	19	522,190	474,498
Other financial assets at amortized cost	18	127,353	81,843
Financial assets at fair value through profit or loss	21	374,573	230,093
Investments measured at amortized cost	17	251,293	—
Pledged bank deposits	22	2,457	2,077
Term deposits	22	2,151,147	2,339,699
Cash and cash equivalents	22	1,026,335	1,172,793
Other current assets	23	79,353	82,980
Total current assets		4,643,158	4,511,422
Total assets		4,858,478	4,911,508
Equity			
Equity attributable to owners of the Company			
Share capital	24	133	131
Treasury shares		(1)	(1)
Other reserves	25	13,086,689	12,948,250
Accumulated deficits		(8,941,785)	(8,866,016)
Non-controlling interests		4,145,036 92,232	4,082,364 73,787
Total equity		4,237,268	4,156,151

Interim Condensed Consolidated Balance Sheet (Continued)

		As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
	Note		
Liabilities			
Non-current liabilities			
Lease liabilities	15	5,673	4,590
Deferred income	28	79,484	79,761
Total non-current liabilities		85,157	84,351
Current liabilities			
Trade and other payables	27	319,416	386,863
Deferred income	28	—	4,208
Salary and welfare payable		153,034	200,615
Contract liabilities	6	41,418	56,943
Current income tax liabilities		234	1,539
Lease liabilities	15	9,971	9,538
Provisions		11,980	11,300
Total current liabilities		536,053	671,006
Total liabilities		621,210	755,357
Total equity and total liabilities		4,858,478	4,911,508

The above interim condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

On behalf of the Board

Gong Yingying

Director

Feng Xiaoying

Director

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Note	Attributable to owners of the Company				Sub-total RMB'000	Non- controlling interests RMB'000	Total equity RMB'000
		Share capital RMB'000	Treasury shares RMB'000	Other reserves RMB'000	Accumulated deficits RMB'000			
Balance at 31 March 2023 (Audited)		131	(1)	12,948,250	(8,866,016)	4,082,364	73,787	4,156,151
Comprehensive income								
Loss for the period		—	—	—	(75,769)	(75,769)	(3,786)	(79,555)
Currency translation differences		—	—	128,572	—	128,572	5,059	133,631
Total comprehensive income for the period		—	—	128,572	(75,769)	52,803	1,273	54,076
Transactions with owners in their capacity as owners:								
Share-based compensation	26	—	—	21,074	—	21,074	—	21,074
Capital injection from non-controlling interests		—	—	—	—	—	1,805	1,805
Issuance of ordinary shares	24(a)	—	—	—	—	—	—	—
Exercise of option and vest of Share Award Scheme	25	2	—	4,160	—	4,162	—	4,162
Disposal of minority interest of subsidiary	25	—	—	(15,367)	—	(15,367)	15,367	—
Total transactions with owners in their capacity as owners		2	—	9,867	—	9,869	17,172	27,041
Balance at 30 September 2023 (Unaudited)		133	(1)	13,086,689	(8,941,785)	4,145,036	92,232	4,237,268
Balance at 31 March 2022 (Audited)		124	(1)	12,227,727	(8,238,050)	3,989,800	17,666	4,007,466
Comprehensive income								
Loss for the period		—	—	—	(353,517)	(353,517)	(2,830)	(356,347)
Currency translation differences		—	—	368,671	—	368,671	2,615	371,286
Total comprehensive income for the period		—	—	368,671	(353,517)	15,154	(215)	14,939
Transactions with owners in their capacity as owners:								
Share-based compensation	26	—	—	44,307	—	44,307	—	44,307
Issuance of ordinary shares	24(a)	—	—	—	—	—	—	—
Exercise of option and vest of Share Award Scheme	25	1	—	288	—	289	—	289
Total transactions with owners in their capacity as owners		1	—	44,595	—	44,596	—	44,596
Balance at 30 September 2022 (Unaudited)		125	(1)	12,640,993	(8,591,567)	4,049,550	17,451	4,067,001

The above interim condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	Note	Six months ended 30 September	
		2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Cash flows from operating activities			
Cash used in operations		(292,844)	(239,018)
Interest received	10	4,639	3,932
Interest paid	10	(946)	(1,639)
Income tax paid		(1,304)	(1,224)
Net cash used in operating activities		(290,455)	(237,949)
Cash flows from investing activities			
Payments for investments in wealth management products	5	(1,125,000)	(998,010)
Proceeds from the redemption of wealth management products	5	986,890	657,824
Payment for investments measured at amortized cost		—	(248,493)
Placement of term deposits		(1,179,560)	(1,970,583)
Payments for property, plant and equipment		(38,019)	(28,700)
Payments for acquisition of intangible assets		(1,650)	(8,356)
Payments for investments in venture capital funds		—	(10,007)
Payments for investments in associates and joint venture	11	(36,367)	—
Withdrawals of term deposits and restricted bank balance and deposits		1,509,014	222,217
Interest on term deposits and restricted bank balance and deposits received		24,371	9,194
Proceeds from disposal of investments accounted for using the equity method	11	—	2,537
Net cash generated from/(used in) investing activities		139,679	(2,372,377)
Cash flows from financing activities			
Proceeds from exercise of option		817	269
Principal elements of lease payments		(6,084)	(13,024)
Capital injection from non-controlling interests		1,805	—
Net cash used in financing activities		(3,462)	(12,755)
Net decrease in cash and cash equivalents			
Cash and cash equivalents at beginning of the period	22	1,172,793	3,408,505
Exchange effect on cash and cash equivalents		7,780	87,555
Cash and cash equivalents at the end of the period		1,026,335	872,979

The above interim condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1 General information

Yidu Tech Inc. (the “Company”) was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability under the Companies Act of the Cayman Islands (Cap. 22, Law 3 of 1961 as consolidated and revised). The address of the Company is Suite#4-210, Governors Square, 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands.

The Company is an investment holding company and its subsidiaries (together, the “Group”) are primarily engaged in the provision of the following services: i) big data platform and solutions; ii) life sciences solutions; and iii) health management platform and solutions in the People’s Republic of China (“PRC”), Brunei and Singapore.

The interim condensed consolidated financial information comprises the interim condensed consolidated balance sheet as at 30 September 2023, the interim condensed consolidated statement of comprehensive income, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six months then ended, and a summary of significant accounting policies and other explanatory notes (the “Interim Financial Information”). The Interim Financial Information is presented in Renminbi (“RMB”), unless otherwise stated.

2 Basis of preparation

The Interim Financial Information for the six months ended 30 September 2023 has been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” (“IAS 34”).

The Interim Financial Information does not include all the notes of the type normally included in an annual financial statements. Accordingly, it should be read in conjunction with the Group’s consolidated financial statements for the year ended 31 March 2023, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by International Accounting Standards Board (“IASB”) and any public announcements made by the Company during the interim reporting period.

3 Accounting policies

The accounting policies applied to the preparation of the Interim Financial Information are consistent with those of applied in the preparation of the Group’s consolidated financial statements for the year ended 31 March 2023.

In addition, certain new and amended standards and annual improvements have been published that are not mandatory for the current reporting period and have not been early adopted by the Group. These new and amended standards and annual improvements are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

4 Critical accounting estimates and judgements

The preparation of the Interim Financial Information requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing the Interim Financial Information, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied in the preparation of the Group's consolidated financial statements for the year ended 31 March 2023.

5 Financial risk management

(a) Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, cash flow and fair value interest rate risk), credit risk and liquidity risk.

The Interim Financial Information does not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's consolidated financial statements for the year ended 31 March 2023. There have been no changes in the risk management policies since 31 March 2023.

(b) Fair value estimation

(i) Fair value hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value in the consolidated financial information. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level follows underneath the table.

Recurring fair value measurements As at 30 September 2023 (Unaudited)	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
Financial assets at fair value through profit or loss				
Wealth management products	—	—	374,573	374,573
Investment in venture capital funds	—	—	20,819	20,819
Total financial assets	—	—	395,392	395,392
Recurring fair value measurements As at 31 March 2023 (Audited)	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
Financial assets at fair value through profit or loss				
Wealth management products	—	—	230,093	230,093
Investment in venture capital funds	—	—	23,115	23,115
Total financial assets	—	—	253,208	253,208

Notes to the Interim Condensed Consolidated Financial Information (Continued)

5 Financial risk management (continued)

(b) Fair value estimation (continued)

(i) Fair value hierarchy (continued)

Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

Level 2: The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

(ii) Valuation techniques used to determine fair values

As at 30 September 2023 and 31 March 2023, investments in venture capital funds are subject to the terms and conditions set forth in the offering prospectus of each fund. The fair value of the investments in venture capital funds are based primarily on the portion of the net asset value ("NAV") reported by the funds that is attributable to the Group. The NAV is derived from the fair value of these funds at the reporting date of the Group (the vast majority of the financial assets reported by the funds are measured at fair value), and the Group understands and evaluates the valuations provided by the general partners of the funds and make necessary adjustments based on the results of the evaluation. The Group has not made any adjustments to the underlying values.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

5 Financial risk management (continued)

(b) Fair value estimation (continued)

(iii) Fair value measurements using significant unobservable inputs (level 3)

	Wealth management products RMB'000	Loan to a third party with warrants to purchase their preferred shares RMB'000	Investment in venture capital fund RMB'000	Investment in unlisted equity securities RMB'000	Total RMB'000
Opening balance at 31 March 2023 (Audited)	230,093	—	23,115	—	253,208
Acquisitions	1,125,000	—	—	—	1,125,000
Redemption	(986,890)	—	(1,948)	—	(988,838)
Changes in fair value recognized in profit or loss	6,370	—	(1,368)	—	5,002
Currency translation differences	—	—	1,020	—	1,020
Closing balance at 30 September 2023 (Unaudited)	374,573	—	20,819	—	395,392
Opening balance at 31 March 2022 (Audited)	25,000	11,927	7,891	8,570	53,388
Acquisitions	998,010	—	7,877	—	1,005,887
Redemption	(657,824)	—	—	—	(657,824)
Changes in fair value recognized in profit or loss	5,847	(11,927)	2,292	(2,388)	(6,176)
Currency translation differences	—	—	1,062	882	1,944
Closing balance at 30 September 2022 (Unaudited)	371,033	—	19,122	7,064	397,219

Notes to the Interim Condensed Consolidated Financial Information (Continued)

5 Financial risk management (continued)

(b) Fair value estimation (continued)

(iii) Fair value measurements using significant unobservable inputs (level 3) (continued)

Description	Fair value		Significant unobservable inputs	Range of inputs		Relationship of unobservable inputs to fair value
	As at	As at		As at	As at	
	30 September	31 March		30 September	31 March	
	2023	2023		2023	2023	
	RMB'000	RMB'000				
	(Unaudited)	(Audited)				
Financial assets at fair value through profit or loss — Wealth management products	374,573	230,093	Expected interest rate	1.65%–2.90%	1.65%–2.85%	The higher the expected interest rate, the higher the fair value
Financial assets at fair value through profit or loss — Investment in venture capital fund	20,819	23,115	NAV of the fund	/	/	The higher the NAV, the higher the fair value

The fair value of financial assets at fair value through profit or loss — Wealth management products is affected by changes in the interest rate. If the expected interest rate had increased/decreased by 1% with all other variables held constant, the loss before income tax for the six months ended 30 September 2023 would have been approximately 0.6 million (six months ended 30 September 2022: 0.4 million) lower/higher.

If the fair values of financial assets at fair value through profit or loss — Investment in venture capital funds held by the Group had been 10% higher/lower, the loss before income tax for the six months ended 30 September 2023 would have been approximately 2.8 million (six months ended 30 September 2022: 1.9 million) lower/higher.

There were no transfers between level 1, 2 and 3 of fair value hierarchy classifications during the six months ended 30 September 2023 and 2022.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

6 Segment information

(a) Disaggregation of revenue from contracts with customers

The Group's business activities, for which discrete financial information are available, are regularly reviewed and evaluated by the Chief Operating Decision Maker ("CODM"). As a result of this evaluation, the Group determined that it has operating segments as follows:

- Big data platform and solutions
- Life sciences solutions
- Health management platform and solutions

CODM assesses the performance of the operating segments mainly based on segment revenue and gross profit of each operating segment which is used by management as a basis for the purpose of resource allocation and assessment of segment performance. The selling and marketing expenses, administrative expenses and research and development expenses are also included in the measurement of the segments' performance. Net impairment losses on financial assets and contract assets, other income, other gains/(losses) — net, finance income — net, shares of loss from investments in associates and income tax expenses are also not allocated to individual operating segments. Revenues from external customers reported to CODM are measured as segment revenue, which is derived from the customers in each segment. Cost of sales and services primarily comprises cost for purchasing of hardware and software, cost of development services, salary and compensation expenses, and others. The segment information provided to CODM is measured in a manner consistent with that applied in these financial information. There was no information on separate segment assets and segment liabilities provided to CODM, as CODM does not use such information to allocate resources to or evaluate the performance of the operating segments. The revenue segment information reported to CODM for the six months ended 30 September 2023 and 2022 is as follows:

Notes to the Interim Condensed Consolidated Financial Information (Continued)

6 Segment information (continued)

(a) Disaggregation of revenue from contracts with customers (continued)

	Six months ended 30 September 2023 (Unaudited)			
	Big data platform and solutions RMB'000	Life sciences solutions RMB'000	Health management platform and solutions RMB'000	Total RMB'000
Revenue from contracts with Customers	127,939	170,163	58,378	356,480
Cost of sales and services	(70,127)	(122,825)	(27,323)	(220,275)
Gross profit	57,812	47,338	31,055	136,205

	Six months ended 30 September 2022 (Unaudited)			
	Big data platform and solutions RMB'000	Life sciences solutions RMB'000	Health management platform and solutions RMB'000	Total RMB'000
Revenue from contracts with Customers	124,028	146,531	203,807	474,366
Cost of sales and services	(72,817)	(125,288)	(152,586)	(350,691)
Gross profit	51,211	21,243	51,221	123,675

For the six months ended 30 September 2023 and 2022, the geographical information on the total revenue is as follows:

	Six months ended 30 September (Unaudited)			
	2023		2022	
	RMB'000	%	RMB'000	%
Mainland China	300,658	84.3%	384,166	81.0%
Rest of the world	55,822	15.7%	90,200	19.0%
	356,480	100%	474,366	100%

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the PRC. For the six months ended 30 September 2023 and 2022, the Group earns approximately 84.3% and 15.7%, 81.0% and 19.0%, of total revenue from external customers located in the PRC and other countries, respectively.

As at 30 September 2023 and 31 March 2023, majority of the non-current assets of the Group were located in the PRC, Brunei, Cayman Islands and British Virgin Islands.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

6 Segment information (continued)

(b) Contract assets and contract liabilities

The Group has recognized the following revenue-related contract assets and liabilities:

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Contract assets (i)		
Big data platform and solutions	394	25,606
Life sciences solutions	115,186	111,628
Health management platform and solutions	3,276	1,469
Less: allowance for impairment of contract assets	(14,132)	(14,997)
	104,724	123,706

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Contract liabilities (ii)		
Big data platform and solutions	15,003	16,748
Life sciences solutions	25,058	36,002
Health management platform and solutions	1,357	4,193
	41,418	56,943

(i) Contract assets are the Group's right to consideration in exchange for goods or services that the Group has transferred to the customer. The decrease in the contract assets is mainly due to the completion of the ART platform solution and Vaccination Management project of the Brunei Government, which was transferred from contract assets to trade receivable.

(ii) Contract liabilities mainly arise from the advanced payments from customers of the i) big data platform and solutions, ii) life sciences solutions, and iii) health management platform and solutions segments upon which the performance obligations have been established while the underlying services are yet to be provided.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

6 Segment information (continued)

(c) Revenue recognized in relation to contract liabilities

The following table shows how much of the revenue recognized in the current reporting period relates to carried-forward contract liabilities.

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Big data platform and solutions	9,562	5,052
Life sciences solutions	22,807	9,579
Health management platform and solutions	1,285	2,531
	33,654	17,162

7 Other income

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Government grants (i)	5,700	5,684
Value added tax reduction	1,316	3,181
Interest income (ii)	65,317	28,663
	72,333	37,528

(i) Government grants

Government grants are mainly funds received for scientific and innovation research projects and awards for scientific and technological innovations enterprises.

(ii) Interest income is from investments measured at amortized cost and term deposits.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

8 Other gains/(losses) — net

	Six months ended 30 September	
	2023	2022
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Net fair value gains/(losses) on financial assets at fair value through profit or loss (i)	5,002	(6,176)
Net foreign exchange losses	(4,381)	(87,238)
Donation	(1,111)	(388)
Other items	627	3,171
	137	(90,631)

- (i) Net fair value gains/(losses) on financial assets at fair value through profit or loss consists of fair value changes of (a) wealth management products; (b) investment in venture capital fund; (c) investment in unlisted equity securities; and (d) loan to a third party with warrants to purchase their preferred shares.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

9 Expenses by nature

Expenses included in cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses are further analysed as follows:

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Employee benefits expenses	262,463	410,362
Outsourcing services fee	124,310	91,464
Consulting and other professional fee	26,672	26,877
Travelling, entertainment and general office expenses	25,436	31,621
Depreciation of property, plant and equipment (note 14)	13,365	12,216
Promotion and advertising expenses	11,230	13,059
Cost of sales	5,852	157,744
Depreciation of right-of-use assets (note 15)	4,884	8,620
Amortization of intangible assets (note 16)	3,937	3,362
Labour dispatching	3,498	6,195
Auditors' remuneration	3,463	2,848
— Auditor of the Company	1,950	1,950
Taxes and surcharges	838	1,131
Other expenses	998	514
Total cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses	486,946	766,013

Notes to the Interim Condensed Consolidated Financial Information (Continued)

10 Finance income and costs

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Finance income		
Interest income on current deposits	4,639	3,932
Finance costs		
Interest expenses for lease liabilities	(946)	(1,639)
Finance income – net	3,693	2,293

11 Investments accounted for using the equity method

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
At beginning of the period	5,282	9,915
Additions (i)	36,367	—
Share of losses from investments in associates	(4,785)	(553)
Disposal of associates (ii)	—	(2,537)
At end of the period	36,864	6,825

- (i) Pursuant to the investment agreement dated 28 October 2022, the Group made an additional cash contribution of US\$5.0 million (equivalent to approximately RMB36.4 million) to YD Capital I L.P. during this period.
- (ii) On 19 August 2022, Guiyang Wudang Yiduyun Medical Healthcare Industry Investment Fund (“Guiyang Wudang Yiduyun”), an associate company completed its liquidation and deregistration. The Group received cash equivalent to approximately RMB2.5 million from Guiyang Wudang Yiduyun upon its liquidation.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

12 Income tax expense

	Six months ended 30 September	
	2023	2022
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current tax (credit)/expense	(2)	1,224
Deferred income tax expense (note 29)	172	612
Income tax expense	170	1,836

Income tax expense is recognized based on the management's best knowledge of the income tax rates that would be applicable to the full financial year.

13 Loss per share

- (a) Basic loss per share is calculated by dividing the loss attributable to the Company's owners by the weighted average number of ordinary shares in issue during the six months ended 30 September 2023 and 2022.

The calculation of loss per share is based on the following:

	Six months ended 30 September	
	2023	2022
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Loss attributable to owners of the Company	(75,769)	(353,517)
Weighted average number of ordinary shares in issue ('000)	1,049,961	988,812
Basic loss per share (RMB yuan)	(0.07)	(0.36)

- (b) Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

As the Group incurred losses for the six months ended 30 September 2023 and 2022, the potential ordinary shares were not included in the calculation of dilutive loss per share, as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended 30 September 2023 and 2022 are the same as basic loss per share for the respective periods.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

14 Property, plant and equipment

	Electronic equipment RMB'000	Office furniture RMB'000	Leasehold improvement RMB'000	Total RMB'000
Cost:				
As at 31 March 2023	116,788	3,123	67,264	187,175
Additions	29,750	1,076	2,847	33,673
Disposal	(443)	(70)	—	(513)
As at 30 September 2023	146,095	4,129	70,111	220,335
Accumulated depreciation:				
As at 31 March 2023	(87,968)	(2,428)	(24,195)	(114,591)
Depreciation	(9,805)	(244)	(3,316)	(13,365)
Disposal	201	65	—	266
As at 30 September 2023	(97,572)	(2,607)	(27,511)	(127,690)
Net carrying amount:				
As at 31 March 2023 (Audited)	28,820	695	43,069	72,584
As at 30 September 2023 (Unaudited)	48,523	1,522	42,600	92,645

Notes to the Interim Condensed Consolidated Financial Information (Continued)

14 Property, plant and equipment (continued)

	Electronic equipment RMB'000	Office furniture RMB'000	Leasehold improvement RMB'000	Total RMB'000
Cost:				
As at 31 March 2022	104,781	2,910	43,838	151,529
Additions	10,897	76	16,108	27,081
Disposal	(468)	—	—	(468)
As at 30 September 2022	115,210	2,986	59,946	178,142
Accumulated depreciation:				
As at 31 March 2022	(74,498)	(1,909)	(15,778)	(92,185)
Depreciation	(7,902)	(280)	(4,034)	(12,216)
Disposal	355	—	—	355
As at 30 September 2022	(82,045)	(2,189)	(19,812)	(104,046)
Net carrying amount:				
As at 31 March 2022 (Audited)	30,283	1,001	28,060	59,344
As at 30 September 2022 (Unaudited)	33,165	797	40,134	74,096

Notes to the Interim Condensed Consolidated Financial Information (Continued)

15 Leases

(a) Amounts recognized in the interim condensed consolidated balance sheets

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Right-of-use assets		
Buildings	13,760	11,249
Lease liabilities		
Current	9,971	9,538
Non-current	5,673	4,590
	15,644	14,128

(b) Amounts recognized in the interim condensed consolidated statements of comprehensive income

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Depreciation charge of right-of-use assets	4,884	8,620
Interest expense	946	1,639

Notes to the Interim Condensed Consolidated Financial Information (Continued)

16 Intangible assets

	Goodwill RMB'000	License RMB'000	Software RMB'000	Technology RMB'000	Total RMB'000
Cost:					
As at 31 March 2023	4,362	36,613	24,991	3,900	69,866
Additions	—	—	4,110	—	4,110
As at 30 September 2023	4,362	36,613	29,101	3,900	73,976
Accumulated amortization:					
As at 31 March 2023	(4,362)	(11,026)	(11,047)	(3,900)	(30,335)
Amortization	—	(851)	(3,086)	—	(3,937)
As at 30 September 2023	(4,362)	(11,877)	(14,133)	(3,900)	(34,272)
Net carrying amount:					
As at 31 March 2023 (Audited)	—	25,587	13,944	—	39,531
As at 30 September 2023 (Unaudited)	—	24,736	14,968	—	39,704

Notes to the Interim Condensed Consolidated Financial Information (Continued)

16 Intangible assets (continued)

	Goodwill RMB'000	License RMB'000	Software RMB'000	Technology RMB'000	Total RMB'000
Cost:					
As at 31 March 2022	4,362	33,451	13,359	3,900	55,072
Additions	—	1,700	5,890	—	7,590
As at 30 September 2022	4,362	35,151	19,249	3,900	62,662
Accumulated amortization:					
As at 31 March 2022	(4,362)	(7,794)	(3,767)	(3,900)	(19,823)
Amortization	—	(823)	(2,539)	—	(3,362)
As at 30 September 2022	(4,362)	(8,617)	(6,306)	(3,900)	(23,185)
Net carrying amount:					
As at 31 March 2022 (Audited)	—	25,657	9,592	—	35,249
As at 30 September 2022 (Unaudited)	—	26,534	12,943	—	39,477

17 Investments measured at amortized cost

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Non-Current assets		
Fixed rate notes	—	240,510
Current assets		
Fixed rate notes	251,293	—

- (a) Investments measured at amortized cost are investments of fixed rate notes issued by Goldman Sachs Finance Corp International Ltd with a maturity of two years, where the contractual cash flows are solely payments of principal and interests. The notes was reclassified as current assets as at 30 September 2023 considering the maturity date of 2 June 2024.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

18 Other financial assets at amortized cost

Other financial assets at amortized cost include the following:

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Interests receivable (a)	62,097	21,151
Deposits of share award scheme trusts (b)	27,635	26,449
Deposits	17,040	18,368
Advances to staff	3,749	2,335
Payments on behalf of the third parties (c)	3,414	3,882
Others	17,431	12,849
	131,366	85,034
Less: provision for impairment of other receivables	(4,013)	(3,191)
	127,353	81,843

- (a) Interests receivable is mainly the interest generated by investments measured at amortized cost and term deposits.
- (b) In November 2021, the Company entered into a Trust Deed constituting Yidu Tech Share Award Trust (the "Trust Deed") with Trident Trust Company (HK) Limited ("Trustee"). The Company and the Trustee established the Trust by the execution of the Trust Deed, and together with the adoption by the Company of the share award scheme rules, for the purpose of encouraging and facilitating the Trustee's purchase and holding, either directly or indirectly, of the shares of the Company, for the benefit of the eligible persons of the Group pursuant to the share award scheme rules and the Trust Deed. The balance represented that the Group from time to time at its sole discretion transferred, paid or credited sums of money to the Trustee for the acquisition of shares to be held on trust in accordance with the Trust Deed and the share award scheme rules.
- (c) In life sciences solutions segment, the Group's travelling and related expenses incurred by its employees that will be reimbursed by the customers as agreed in the contracts.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

19 Trade receivables

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Trade receivables from contracts with customers		
— Third parties	640,839	581,506
Less: allowance for impairment of trade receivables	(118,649)	(107,008)
	522,190	474,498

- (a) The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 180 days. The aging analysis of the trade receivables based on invoice date is as follows:

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
— Up to 3 months	211,521	239,847
— 3 to 6 months	76,271	17,520
— 6 months to 1 year	112,572	93,067
— 1–2 years	181,075	178,274
— Over 2 years	59,400	52,798
Less: allowance for impairment of trade receivables	(118,649)	(107,008)
Total	522,190	474,498

(b) **Fair values of trade receivables**

Due to the short-term nature of the current receivables, their carrying amounts are considered to be approximately the same as their fair values.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

19 Trade receivables (continued)

(c) The movements on the provision for impairment of trade receivables are as follows:

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
At beginning of the period	(107,008)	(85,729)
Provision for impairment of trade receivables	(20,340)	(10,728)
Write off of trade receivables	8,699	33,891
At end of the period	(118,649)	(62,566)

20 Inventories

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Purchased goods — at cost	6,310	6,310
Less: allowance for impairment of inventories	(2,577)	(2,577)
	3,733	3,733

Notes to the Interim Condensed Consolidated Financial Information (Continued)

21 Financial assets at fair value through profit or loss

The Group classifies the following financial assets at fair value through profit or loss:

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Non-Current assets		
Investment in venture capital funds (i)	20,819	23,115
Current assets		
Investment in wealth management products (ii)	374,573	230,093

- (i) On 12 May 2021, the Company entered into an subscription agreement with Bits x Bites Growth Fund I, L.P. for a subscription of US\$1.5 million in this venture capital fund, of which the remaining US\$0.15 million will be paid in 2024.

On 11 May 2022, the Company entered into an subscription agreement with TruMed Health Innovation Fund LP for a subscription of US\$3 million in this venture capital fund, of which the remaining US\$1.73 million will be paid by 2028.

- (ii) The wealth management products ("WMP") of the Group as at 30 September 2023 were purchased from local banks in China. The WMP were principal protected with maturity within 3 months. The expected interest rate of WMP was 1.65%–2.90% (2022: 1.65%–2.85%) per annum and interest will be paid on the maturity date.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

22 Cash and bank balances

(a) Cash and cash equivalents

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Bank balances, term deposits, pledged bank deposits and restricted bank balance and deposits	3,191,294	3,522,039
Less:	(2,164,959)	(2,349,246)
Term deposits	(2,151,147)	(2,339,699)
Pledged bank deposits	(7,561)	(3,339)
Restricted bank balance and deposits with initial terms over three months*	(6,251)	(6,208)
Cash and cash equivalents	1,026,335	1,172,793

* Restricted bank balance and deposits are deposited in an escrow account with China CITIC Bank Co., LTD. Ningbo Branch for the registered capital of subsidiary Yinshu Insurance Broker Co., Ltd. to operate insurance brokerage business.

The directors of the Company considered that the carrying amount of the term deposits, pledged bank deposits and restricted bank balance and deposits with initial terms over three months approximated to their fair value as at 30 September 2023 and 31 March 2023.

The weighted average effective interest rate of the term deposits and restricted bank balance and deposits of the Group for the six months ended 30 September 2023 and 31 March 2023 are 5.06% and 4.65% respectively.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

22 Cash and bank balances (continued)

(a) Cash and cash equivalents (continued)

Bank balances, term deposits, pledged bank deposits and restricted bank balance and deposits of the Group are denominated in the following currencies:

	As at 30 September 2023 RMB'000	As at 31 March 2023 RMB'000
US\$	2,749,476	2,527,296
RMB	419,775	904,732
HK\$	8,331	86,577
SGD (Singapore Dollar)	7,459	2,829
BND (Brunei Dollar)	6,253	605
Total	3,191,294	3,522,039

(b) Pledged bank deposits

	As at 30 September 2023 RMB'000	As at 31 March 2023 RMB'000
Non-current assets	5,104	1,262
Current assets	2,457	2,077
Total	7,561	3,339

Pledged bank deposits represent deposits pledged to banks to obtain letters of guarantees for the fulfilment of certain contracts.

Pledged bank deposits of the Group are all denominated in RMB and carried interests at market rates at 0.3% as at 30 September 2023 and 31 March 2023.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

23 Other current assets

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Prepayment:		
Prepaid cloud storage and other service fee	46,616	54,795
Advance payments to suppliers for inventories	1,447	1,974
Others	2,820	2,157
Deductible input VAT	29,852	25,963
Less: provision for impairment of advance payments to suppliers for inventories	(1,382)	(1,909)
Other current assets	79,353	82,980

24 Share capital

	Number of shares	Share capital US\$'000	Share capital RMB'000
Issued:			
As at 31 March 2023 (Audited)	1,035,557,785	21	131
Newly issued ordinary shares (a)	362,089	—	—
Exercise of option vesting (Note 26(a))	16,938,275	—	2
As at 30 September 2023 (Unaudited)	1,052,858,149	21	133
As at 31 March 2022 (Audited)	987,141,040	20	124
Newly issued ordinary shares (a)	2,326,637	—	—
Exercise of option vesting (Note 26(a))	2,804,000	—	1
As at 30 September 2022 (Unaudited)	992,271,677	20	125

(a) On 1 April 2023 and 1 July 2023, the Company also issued 319,764 and 42,325 shares under the Post-IPO Share Award Scheme.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

25 Other reserves

	Share-based compensation reserve RMB'000	Currency translation differences RMB'000	Share premium RMB'000	Other reserves RMB'000	Total RMB'000
As at 31 March 2023 (Audited)	375,482	550,864	11,840,429	181,475	12,948,250
Share-based compensation (note 26)	21,074	—	—	—	21,074
Exercise of options	(167,652)	—	171,812	—	4,160
Vesting of Post-IPO Share Award Scheme	(18,320)	—	18,320	—	—
Disposal of minority interest of subsidiary	—	—	(15,367)	—	(15,367)
Currency translation differences	—	128,572	—	—	128,572
As at 30 September 2023 (Unaudited)	210,584	679,436	12,015,194	181,475	13,086,689
As at 31 March 2022 (Audited)	426,565	251,418	11,368,269	181,475	12,227,727
Share-based compensation (note 26)	44,307	—	—	—	44,307
Exercise of options	(14,310)	—	14,598	—	288
Vesting of Post-IPO Share Award Scheme	(43,931)	—	43,931	—	—
Currency translation differences	—	368,671	—	—	368,671
As at 30 September 2022 (Unaudited)	412,631	620,089	11,426,798	181,475	12,640,993

Notes to the Interim Condensed Consolidated Financial Information (Continued)

26 Share-based compensation

(a) Share Option Scheme

Share Option Scheme includes Pre-IPO Share Option Scheme and Post-IPO Share Option Scheme. Please refer to the Group's consolidated financial statements for the year ended 31 March 2023 for details about the two schemes.

Pursuant to the resolution of the Shareholders on 28 December 2020, the shareholders of the Company approved the adoption of the Post-IPO Share Option Scheme to grant options to the Group's employees and service providers. The vesting period of the Post-IPO Share Option Scheme is 0 to 4 years subject to employees and service providers' continuous service to the Company. In addition, the Directors established performance conditions for certain employees, against the attainment of these conditions the options vested to them. The performance conditions include business, financials and operations for the Group's business segments. The Company granted 6,058,500 options to its employees under Post-IPO Share Option Scheme for the six months ended 30 September 2023. Pursuant to the resolution of the Board on 25 August 2023, the Post-IPO Share Option Scheme was terminated.

Movements in the number of share options granted to employees and service providers are as follows:

	Six months ended 30 September			
	2023		2022	
	(Unaudited)		(Unaudited)	
	Average	Number of	Average	Number of
	exercise price		exercise price	
	per share	options	per share	options
	option		option	
At beginning of the period	US\$0.406	69,839,179	US\$0.301	96,321,362
Granted during the period	US\$0.755	6,058,500	US\$1.126	612,900
Exercised during the period	US\$0.022	(16,938,275)	US\$0.015	(2,804,000)
Forfeited during the period	US\$0.645	(3,931,560)	US\$0.010	(4,049,321)
At end of the period	US\$0.546	55,027,844	US\$0.328	90,080,941

No options expired during the period covered by the above table.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

26 Share-based compensation (continued)

(a) Share Option Scheme (continued)

The Company have used Binomial option-pricing model to determine the fair value of the share options as at the grant date. Key assumptions are set as below:

	Six months ended 30 September	
	2023 (Unaudited)	2022 (Unaudited)
Grant date	3 July 2023	22 April 2022
Fair value per ordinary share	HK\$5.46	HK\$8.43
Exercise price	HK\$5.91	HK\$8.83
Risk-free interest rate	3.7%	3.0%
Dividend Yield	—	—
Volatility	47%	48%
Expected terms	10 years	10 years

The weighted average remaining contractual life of share options outstanding as at 31 March 2023 and 30 September 2023 is 5.66 year and 6.26 year, respectively.

(b) Post-IPO Share Award Scheme

Pursuant to the resolution of the Shareholders on 28 December 2020, the Post-IPO Share Award Scheme was adopted to align the interests of eligible persons with those of the Group and to encourage and retain eligible persons to make contributions to the long-term growth and profits of the Group. On 28 September 2023, The shareholders approved at the Company's 2023 annual general meeting that the Post-Share Award Scheme is amended to bring it in line with the amendments to the Listing Rules. The awards granted under the Post-IPO Share Award Scheme prior to the amendment, but not yet vested shall continue to be valid and be vested in accordance with the amended Post-IPO Share Award Scheme. An award granted under the Post-IPO Share Award Scheme may be vested in the form of award shares or the actual selling price of the award shares in cash, as the board of directors of the Company may determine in accordance with the related rules. The aggregate number of Shares underlying all grants made pursuant to the Post-IPO Share Award Scheme (excluding Award Shares which have been forfeited in accordance with the Post-IPO Share Award Scheme) will not exceed 105,285,214 Shares without Shareholders' approval subject to a limit of 10% of the total number of issued Shares at the date of approval of the amendment of the Post-IPO Share Award Scheme. The vesting period of the Post-IPO Share Award Scheme is 0 to 4 years subject to employees and service providers' continuous service. Besides that, the Directors established performance conditions for certain employees, against the attainment of these conditions the options vested to them. The performance conditions include business, financials and operations for the Group's business segments.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

26 Share-based compensation (continued)

(b) Post-IPO Share Award Scheme (continued)

(i) Grant of the shares under the Post-IPO Share Award Scheme during the six months ended 30 September 2023

On 1 April 2023 and 25 August 2023, 260,800 and 10,079,360 shares were granted to employees, respectively. Altogether, 10,340,160 shares and 4,374,100 shares were granted during the six months ended 30 September 2023 and 2022.

(ii) Fair value of shares under the Post-IPO Share Award Scheme

The fair value of shares granted on 1 April 2023 was assessed to approximate to the market price of the grant date at the amount of HK\$7.32 each (equivalent to RMB1,729,605 in total).

The fair value of shares granted on 25 August 2023 was assessed to approximate to the market price of the grant date at the amount of HK\$4.14 each (equivalent to RMB37,806,067 in total).

Movements in the number of shares granted and the respective weighted average grant date fair value are as follows:

	Six months ended 30 September			
	2023 (Unaudited)		2022 (Unaudited)	
	Number of shares under Post-IPO Share Award Scheme	Weighted average fair value per shares (HK\$)	Number of shares under Post-IPO Share Award Scheme	Weighted average fair value per shares (HK\$)
As at 31 March (Audited)	14,246,384	27.44	7,802,690	32.41
Granted during the period	10,340,160	4.22	4,374,100	9.37
Exercised during the period	(2,909,204)	16.62	(3,039,056)	16.87
Forfeited during the period	(4,592,613)	8.74	(2,094,800)	29.64
As at 30 September (Unaudited)	17,084,727	20.26	7,042,934	25.63

Notes to the Interim Condensed Consolidated Financial Information (Continued)

26 Share-based compensation (continued)

(b) Post-IPO Share Award Scheme (continued)

(ii) Fair value of shares under the Post-IPO Share Award Scheme (continued)

Total expenses arising from share-based payment transactions recognised during six months ended 30 September 2023 and 2022 as part of employee benefits expenses were as follows:

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Options issued under Share Option Scheme	10,831	10,970
Shares issued under Share Award Scheme	10,243	33,337
	21,074	44,307

27 Trade and other payables

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Trade payables	177,921	160,426
Tax payables	16,716	10,172
Other payables:		
— Payables for consulting and other service fee	39,008	45,266
— Insurance premium collection payables (i)	31,204	130,673
— Insurance claims collection payables	14,090	—
— Payables for repurchase of options	11,229	10,747
— Accrual for marketing and sales promotion expenses	6,106	6,469
— Reimbursement payable to employees	5,802	7,370
— Accrual for office expenses	5,028	2,287
— Payables for leasehold improvement	3,219	5,698
— Payables for purchase of fixed assets and intangible assets	1,090	1,953
— Others	8,003	5,802
	319,416	386,863

- (i) Insurance premium collection payables are insurance premiums collected on behalf of insurance companies but not yet remitted to them as at 30 September 2023.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

27 Trade and other payables (continued)

- (a) The carrying amounts of trade and other payables are considered to be approximated to their fair values, due to their short-term nature.
- (b) Aging analysis of the trade payables based on invoice date at the end of each reporting period are as follows:

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
— Up to 3 months	53,764	55,009
— 3 to 6 months	4,107	5,955
— 6 months to 1 year	29,882	28,441
— 1 to 2 years	83,187	69,306
— 2 to 3 years	6,420	1,317
— over 3 years	561	398
	177,921	160,426

28 Deferred income

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Deferred government grants	79,484	83,969
Less: amounts to be realised within the next 12 months	—	(4,208)
Non-current	79,484	79,761

Deferred income represents government grants received but yet to recognize in other income amounted to approximately of RMB79.5 million and RMB84.0 million, respectively, as at 30 September 2023 and 31 March 2023. These government grants are mainly for funding research and development expenditures undertaken by the Group.

Notes to the Interim Condensed Consolidated Financial Information (Continued)

29 Deferred income tax assets and liabilities

- (a) The analysis of deferred income tax assets and deferred income tax liabilities (prior to any offset pursuant to net-off provisions) is as follows:

	As at 30 September 2023 RMB'000 (Unaudited)	As at 31 March 2023 RMB'000 (Audited)
Deferred income tax assets:		
— Deferred income tax assets to be recovered after more than 12 months	423	252
— Deferred income tax assets to be recovered within 12 months	1,749	1,574
	2,172	1,826
Deferred income tax liabilities:		
— Deferred income tax liabilities to be settled after more than 12 months	(505)	(145)
— Deferred income tax liabilities to be settled within 12 months	(1,494)	(1,336)
	(1,999)	(1,481)
	173	345

- (b) The net movement on the deferred income tax account is as follows:

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
At beginning of the period	345	1,238
Charged to profit or loss (note 12)	(172)	(612)
At end of the period	173	626

Notes to the Interim Condensed Consolidated Financial Information (Continued)

30 Related party transactions

(a) Key management personnel compensation

Key management includes directors and senior officers. The compensations paid or payable to key management for employee services are shown below:

	Six months ended 30 September	
	2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Wages, salaries and bonuses	6,316	5,198
Pension costs — defined contribution plans	87	149
Other social security costs	299	90
Housing benefits	57	108
Share-based compensation	5,880	—
	12,639	5,545

No other significant transactions were carried out between the Group and its related parties during the six months ended 30 September 2023 and 2022.

31 Contingent liabilities

The Group did not have any material contingent liabilities as at 30 September 2023.

32 Dividend

No dividend has been paid or declared by the Company or the companies now comprising the Group during the six months ended 30 September 2023 and 2022.

33 Subsequent events

There were no material subsequent events during the period from October 1, 2023 to the approval date of these consolidated financial statements by the Board on November 29, 2023.

DEFINITIONS

“associate”	has the meaning ascribed to it under the Listing Rules
“Audit Committee”	the audit committee of the Board
“Beijing Causa Health”	Beijing Causa Health Technology Co., Ltd.* (北京因數健康科技有限公司), a limited liability company established under the laws of the PRC on April 9, 2015 and a Consolidated Affiliated Entity of our Company
“Beijing Yiyi Cloud”	Beijing Yiyi Cloud Technology Co., Ltd.* (北京懿醫雲科技有限公司), a limited liability company established under the laws of the PRC on 15 January 2015 and an indirect wholly-owned subsidiary of our Company
“Beijing Zhongshi Hanming”	Beijing Zhongshi Hanming Enterprise Co., Ltd.* (北京中世漢明實業有限公司), a limited liability company established under the laws of the PRC on 8 June 2010 and a Consolidated Affiliated Entity of our Company
“Board”	the board of Directors
“China” or “PRC”	the People’s Republic of China and for the purposes of this interim report only, except where the context requires otherwise, excluding Hong Kong, the Macao Special Administrative Region of the People’s Republic of China and Taiwan
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”, “our Company”, or “the Company”	Yidu Tech Inc. (醫渡科技有限公司) (formerly known as “Yidu Inc.” and “Happy Life Tech Inc.”), a company with limited liability incorporated in the Cayman Islands on 9 December 2014
“Consolidated Affiliated Entity(ies)”	entities we control through the Contractual Arrangements, namely Guizhou Yidu Cloud Technology Co., Ltd.* (貴州醫渡雲技術有限公司), Tianjin Happy Life Technology Co., Ltd.* (天津開心生活科技有限公司), Beijing Causa Health Technology Co., Ltd.* (北京因數健康科技有限公司) and Beijing Zhongshi Hanming Enterprise Co., Ltd.* (北京中世漢明實業有限公司) and their respective subsidiaries
“Contractual Arrangement(s)”	the series of contractual arrangements entered into between the wholly foreign-owned enterprises, the Onshore Holdcos and the registered shareholders (as applicable)

Definitions (Continued)

“Controlling Shareholder(s)”	has the meaning ascribed thereto under the Listing Rules and unless the context otherwise requires, refers to Ms. Gong and Sweet Panda Limited
“Corporate Governance Code”	the Corporate Governance Code and Corporate Governance Report set out in Appendix 14 of the Listing Rules, as amended, supplemented or otherwise modified from time to time
“Director(s)”	the director(s) of our Company
“Global Offering”	the Hong Kong Public Offering and the International Offering as defined and described in the Prospectus
“Group”, “we” or “us”	the Company, its subsidiaries, and the Consolidated Affiliated Entities from time to time, and where the context requires, in respect of the period prior to our Company becoming the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of our Company at the relevant time
“HK” or “Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“IFRS”	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
“Latest Practicable Date”	15 December 2023, being the latest practicable date prior to the printing of this interim report for ascertaining certain information contained herein
“Listing”	the listing of the Shares on the Main Board of the Stock Exchange
“Listing Date”	15 January 2021, the date which the Shares were listed on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the GEM of the Stock Exchange
“MNC”	multi-national pharmaceutical companies
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 of the Listing Rules

Definitions (Continued)

“Ms. Gong”	Ms. Gong Yingying, our founder, executive Director, Chairlady and our Controlling Shareholder
“Nomination Committee”	the Nomination Committee of the Board
“Onshore Holdcos”	Yidu Cloud Guizhou, Tianjin Happy Life, Beijing Causa Health and Beijing Zhongshi Hanming
“Post-IPO Share Award Scheme”	the post-IPO share award scheme approved and adopted by our Company on 28 December 2020 with effect from Listing and amended on 28 September 2023
“Post-IPO Share Option Scheme”	the post-IPO share option scheme approved and adopted by our Company on 28 December 2020 with effect from Listing and terminated on 28 September 2023
“Pre-IPO Share Option Plans”	the two pre-IPO share option plans adopted by the Company on 16 March 2015 as amended from time to time
“Prospectus”	the prospectus of the Company dated 31 December 2020
“Remuneration Committee”	the remuneration committee of the Board
“Reporting Period”	six months ended 30 September 2023
“RMB”	Renminbi, the lawful currency of China
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Share(s)”	Ordinary share(s) in the share capital of our Company, currently with a par value of US\$0.00002 each
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary” or “subsidiaries”	has the meaning ascribed thereto in section 15 of the Companies Ordinance
“United States” or “U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US\$”	United States dollars, the lawful currency of the United States

Definitions (Continued)

“Yidu Cloud Guizhou” Guizhou Yidu Cloud Technology Co., Ltd.* (貴州醫渡雲技術有限公司), a limited liability company established under the laws of the PRC on 10 July 2018 and a Consolidated Affiliated Entity of our Company

“%” per cent

* The English names of the PRC entities, PRC laws or regulations, and the PRC governmental authorities referred to in this interim report are translations from their Chinese names and are for identification purposes only.



医渡科技
YIDUTECH